University of Kentucky

UKnowledge
Theses and Dissertations--Kinesiology and
Health Promotion

Kinesiology and Health Promotion

2017

THE EFFECTS OF A WORKSITE WELLNESS PROGRAM ON
PRESCRIPTION CLAIMS
Carrie DeAnn Davidson
University of Kentucky, carrie.davidson@uky.edu
Author ORCID Identifier:

https://orcid.org/0000-0002-8080-760X

Digital Object Identifier: https://doi.org/10.13023/ETD.2017.214

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Davidson, Carrie DeAnn, "THE EFFECTS OF A WORKSITE WELLNESS PROGRAM ON PRESCRIPTION
CLAIMS" (2017). Theses and Dissertations--Kinesiology and Health Promotion. 40.
https://uknowledge.uky.edu/khp_etds/40

This Doctoral Dissertation is brought to you for free and open access by the Kinesiology and Health Promotion at
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Kinesiology and Health Promotion by
an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Carrie DeAnn Davidson, Student
Dr. Melody Noland, Major Professor
Dr. Heather Erwin, Director of Graduate Studies

THE EFFECTS OF A WORKSITE WELLNESS PROGRAM ON PRESCRIPTION
CLAIMS

______________________________
DISSERTATION
__________________________________________
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Education in the College of Education at the University of Kentucky

By
Carrie DeAnn Davidson
Versailles, Kentucky
Director: Dr. Melody Noland, Professor of Kinesiology and Health Promotion
Lexington, Kentucky
2017
Copyright © Carrie DeAnn Davidson 2017

ABSTRACT OF DISSERTATION

THE EFFECTS OF A WORKSITE WELLNESS PROGRAM ON PRESCRIPTION
CLAIMS
The purpose of this study was to determine the effectiveness of the worksite wellness
weight loss program called Weight Loss Matters (WLM) for employees at the University
of Kentucky. The three main objectives were to measure the effect of Weight Loss
Matters for employees from June 2006 to December 2011 in the following areas (1)
prescription claims for hypertension, diabetes, and dyslipidemia, (2) weight loss, and (3)
food diary compliance. Participants included 591 employees who participated in WLM
for at least one session from 2006 to 2011 for whom there were data. This study
employed a Quasi-experiment, longitudinal design. Data were collected from WLM
records and UK health plan records. Data obtained from WLM included attendance,
physical activity reported, food diary compliance, participation goal, height, and weight.
Measures from the health plan database were prescription claims for hypertension,
diabetes, and cholesterol at twelve months prior to start date, six months post-start date,
and 12 months post-start date for each participant. Data analysis included Chi Square,
Fishers Exact, ANOVA, ANCOVA, linear and logistic regression. After completing two
sessions of WLM, a significant number of participants ceased taking hypertension
medications at six and 12 months post-WLM. There was significant weight loss for all
participants after one class. For continued attendance (multiple sessions,) participants
continued to have small weight losses. Analysis showed a significant relationship
between weight loss and food diary completion, with the more food diaries completed,
the more weight was lost. Food diary compliance and attendance were significant
predictors of weight loss. Information gained from this study will be helpful in designing
future weight loss programs at the University of Kentucky and may be useful for similar
worksite wellness weight loss programs.
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Chapter 1
Introduction
Among the leading causes of death in the United States, heart disease, diabetes,
and obesity-related illnesses are among the top ten (Centers for Disease Control and
Prevention, 2009). Many worksites address these issues by implementing worksite
wellness programming. “The worksite, where Americans spend roughly one-third of
their average day, may be the most well-suited environment for health-behavior change
(i.e., health promotion programs) because of convenience and accessibility” (Astrup,
McGovern, & Kochevar, 1992, p. 42). Traditional worksite wellness efforts include such
programs as smoking cessation, stress management, physical activity, and
nutrition/weight loss. Weight loss programs within worksite wellness programs are of
particular interest because of the impact they may have on diabetes, hypertension and
dyslipidemia; all of which are contributors to heart disease, diabetes, or obesity related
illnesses. In order to effectively evaluate a specific worksite wellness weight loss
program, the evaluation must consider the impact of these three conditions.
When evaluating worksite wellness programs, return on investment (ROI) is the
process used to determine if the financial cost of administering the program is paying off
in return. In others words, is the program a wise investment? Worksite wellness ROI is
not often separated into individual program evaluations, but evaluated as a whole.
Different studies have attempted to evaluate ROI in different ways; some looking just at
weight loss programs, others looking at many types of intervention programs. Astrup,
McGovern, and Kochevar (1992) looked at health care claims and absenteeism.
Bungum, Satterwhite, Jackson, and Morrow (2003) assessed only obesity related health
1

care costs and absenteeism. Renaud et al. (2008) included overall health profiles,
employee absenteeism and turnover, and qualitative interview data from managers.
Trogdon, Finkelstein, Reyes, and Dietz (2009) assessed medical costs and absenteeism
with average weight loss. The interest of this study is to only evaluate a weight loss
program, separate from other interventions, and its effect on prescription claims. Instead
of conducting a return on investment in dollar amounts, this study hoped to find value on
the investment.
Avenell et al. (2004) reported lifestyle modifications are comparable to drug
treatments in terms of effectiveness, but Gustafson et al. (2009) specifically showed cost
effectiveness of weight loss compared to life years gained. Wang et al. (2006) examined
higher BMIs compared to cost and showed a lower BMI was associated with lower
healthcare costs. Finkelstein, Linnan, Tate, and Leese (2009) and Carls et al. (2011)
completed longitudinal studies comparing weight loss and health care costs,
demonstrating more weight loss correlated with lower costs. Hughes, Girolami, Cheadle,
Harris, and Patrick (2007) also reviewed the cost savings of weight loss in worksite
wellness programs by checking prescription drug claims of employees in three Fortune
500 companies and found a decrease in prescription drug usage. These studies all
demonstrated a reduction in weight led to a reduction in healthcare costs. The current
study hoped to find a reduction in weight associated with a cessation of medication,
showing value.
Worksites function as a community all on their own, having a particular culture
specific to the workplace. Individual health behavior changes have been proven to be
more effective in the workplace than organizational interventions; however, interventions
aimed at a specific culture can be beneficial (Goldgruber & Ahrens, 2010). Goldgruber
2

and Ahrens concluded that worksite wellness programs must be adapted to the specific
culture or community for which they are intended, but still be aimed at the individual
level. In a study by Renaud, et al. (2008) personalized health promotion programs in the
workplace were successful. The UK Health and Wellness program for employees
conducts a weight loss program entitled Weight Loss Matters (WLM), which is an
example of the type of program discussed by Goldgruber and Ahrens and Renaud, et al.
WLM, while aimed at the individual, has been personalized over the duration of the
program to meet the cultural needs of the UK Community.
The literature supports utilizing the Transtheoretical model (TTM) of behavior
change for worksite wellness weight loss programs. Weight Loss Matters is loosely
based on the TTM. While it frames the program, the TTM does not frame the study,
necessarily. Johnson and colleagues found, “individualized stage-matched, multiple
behavior interventions had significant effects on progression to Action/Maintenance for
healthy eating, exercise, managing emotional distress, and weight among those most at
risk (i.e., those in pre-action) one year post intervention” (2008, p. 244). This study is
similar to WLM in that the main goal was weight loss; and the study showed that weight
loss was sustained post-intervention. Similarly, WLM addresses several health behaviors.
Logue et al. (2004) found that the longer a person spends in the action or maintenance
stages of change, the more likely that person is to lose weight successfully. WLM allows
participants to repeat the program as many times as desired and this can aid in weight loss
and maintenance of the healthy behavior, thereby being successful. As Logue et al.
(2004) pointed out, the longer people are actively losing weight or maintaining their
weight, the more successful they are with weight loss. DiNoia and Prochaska (2010)
examined the decisional balance relationship to stages of change for dietary behaviors.
3

The authors discovered during precontemplation, the cons are higher than the pros and
during action and maintenance, the reverse is true (DiNoia & Prochaska, 2010). In other
words, when a person is considering a change, but has made no attempt at changing, there
are more negative thoughts toward the behavior than positive ones. However, when a
person has taken steps toward the change or is maintaining a change there are more
positive thoughts toward the behavior than negative thoughts. Because participants are
allowed to stay in WLM without a fee as long as they are meeting their goals, more time
is allowed to build more pros than cons and therefore end in more successful weight loss.
Participants are more likely to keep the weight off and change their behaviors if they
accept more pros than cons. O’Connell and Velicer (1988) pointed out two studies where
decisional balance pro/con decisions demonstrated a successful behavior change of
weight loss. Finally, O’Connell and Velicer (1988) added that the move from
contemplation to action may be the time most important in terms of decisional balance.
The TTM has been demonstrated as highly important in changing health behaviors
related to weight loss and control, particularly the constructs of decisional balance and
stages of change (O’Connell & Velicer, 1988). UK Health and Wellness has employed
the TTM in the development of WLM, but this model lacks sensitivity to the culture of
the worksite to promote behavior change.
To address culture in health promotion programming, the ecological model has
been used and adapted over time. McLeroy, Bibeau, Steckler, and Glanz (1988) give a
history of how the model has been adapted and changed over time to not only address the
individual, but also the individuals support network (family and friends), the social
environment, community factors, and public policy. The model was adapted again by
Bronfenbrenner in 1979 into three main systems: the microsystem, mesosystem, and
4

exosystem and called the socio-economic model. The idea of this model is that all three
levels effect each other. When one changes, the other levels change, too. The socioeconomic model serves as a better framework for this study.
Purpose of the Study
The worksite is an opportune place to conduct weight loss programs which can
have a significant impact on disease, certain causes of death and possibly ROI due to the
reduced cost of medications for lifestyle behavior changes. Weight loss programs have
proven effective in the management of many chronic diseases, including hypertension,
diabetes, and dyslipidemia. But, few programs have evaluated the effect of a weight loss
program or weight loss on specific medications prescribed for weight-related conditions
such as blood pressure, high cholesterol and diabetes in a worksite wellness environment.
Astrup, McGovern, and Kochevar (1992), Bungum, Satterwhite, Jackson, and
Morrow (2003), Renaud et al. (2008), and Trogdon, Finkelstein, Reyes, and Dietz (2009)
all show promise in demonstrating the cost effectiveness and positive health effects of
worksite wellness weight loss programs, but further research needed to be conducted.
Determining the effectiveness of the worksite wellness weight loss program at UK
needed to be researched, as it had yet to be evaluated and had collected enough data for
analysis.
The purpose of this study was to determine the effectiveness of the worksite
wellness weight loss program called Weight Loss Matters for employees at the University
of Kentucky. More specifically, the purpose of this study was to measure the effect of
Weight Loss Matters on prescription claims, weight loss, and food diary compliance’s
effect on weight loss from June 2006 to December 2011.

5

Research Questions/Hypotheses
The following are the research questions and research hypotheses:
1. Will UK employees who complete one 10-week session of WLM cease taking
blood pressure medication six months after WLM compared to those who did not
complete one session of WLM?
2. Will UK employees who complete one session of WLM cease taking blood
pressure medication 12 months after WLM compared to those who did not
complete one session of WLM?
3. Will UK employees who complete one session of WLM cease taking diabetes
medication six months after WLM compared to those who did not complete one
session of WLM?
4. Will UK employees who complete one session of WLM cease taking diabetes
medication 12 months after WLM compared to those who did not complete one
session of WLM?
5. Will UK employees who complete one session of WLM cease taking cholesterol
medication six months after WLM compared to those who did not complete one
session of WLM?
6. Will UK employees who complete one session of WLM cease taking cholesterol
medication 12 months after WLM compared to those who did not complete one
session of WLM?
7. What is the attendance compliance rate that best affects weight loss after the first
session?
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8. Is there a statistically significant relationship between percent body weight lost in
UK employees and compliance rate after one session of WLM controlling for
sex?
9. Is there a statistically significant relationship between body weight lost in UK
employees and food diary compliance in UK employees who completed one
session of WLM?
10. Will physical activity level, sex, food diary compliance, weight loss goal, and age
predict a change in weight for UK employees who completed WLM?
11. Will food diary compliance, physical activity level, sex, age, weight loss goal, and
weight change predict a change in blood pressure prescription claims six or 12
months after one session of WLM?
12. Will food diary compliance, physical activity level, sex, age, weight loss goal,
and weight change predict a change in cholesterol prescription claims six or 12
months after one session of WLM?
13. Will food diary compliance, physical activity level, sex, age, weight loss goal, and
weight change predict a change in diabetes prescription claims six or 12 months
after one session of WLM?
Hypotheses:
1. Hypothesis 1: UK employees will cease taking blood pressure medications six
months after completing one session of WLM compared to UK employees who
did not complete one session of WLM.
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2. Hypothesis 2: UK employees will cease taking blood pressure medications 12
months after completing one session of WLM compared to UK employees who
did not complete one session of WLM.
3. Hypothesis 3: UK employees will cease taking diabetes medications six months
after completing one session of WLM compared to UK employees who did not
complete one session of WLM.
4. Hypothesis 4: UK employees will cease taking diabetes medications 12 months
after completing one session of WLM compared to UK employees who did not
complete one session of WLM.
5. Hypothesis 5: UK employees will cease taking cholesterol medications six
months after completing one session of WLM compared to UK employees who
did not complete one session of WLM.
6. Hypothesis 6: UK employees will cease taking cholesterol medications 12 months
after completing one session of WLM compared to UK employees who did not
complete one session of WLM.
7. Hypothesis 7: The higher the attendance rate (attendance of WLM classes), the
more weight lost in UK employees at the end of the first WLM session.
8. Hypothesis 8: Percent of body weight lost (weight lost/starting body weight) for
male and female UK employee will increase with increase attendance compliance
after one session of WLM.
9. Hypothesis 9: Percent of body weight lost (weight lost/starting body weight) for
UK employees who completed one session of WLM will increase with increased
food diary compliance.
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10. Hypothesis 10: A composite of variables: physical activity level, sex, food diary
compliance, weight loss goal, and age will significantly predict a change in
percent body weight.
11. Hypothesis 11: A composite of variables including food diary compliance,
physical activity level, sex, age, weight loss goal, and percent body weight lost
will significantly predict a change in blood pressure prescription claims.
12. Hypothesis 12: A composite of variables including food diary compliance,
physical activity, sex, age, weight loss goal, and percent body weight lost will
significantly predict a change in cholesterol prescription claims.
13. Hypothesis 13: A composite of variables including food diary compliance,
physical activity level, sex, age, weight loss goal, and percent body weight lost
will significantly predict a change in diabetes prescription claims.
Definition of Terms
For this study, the following terms and their definitions were used:
Transtheoretical model-“an integrative framework for understanding how individuals
and populations progress toward adopting and maintain health behavior change for
optimal health” (McKenzie, Neiger, Smeltzer, 2005, p.155.)
Prescription claims-Claims made against the health plan by University of Kentucky
employees for prescription medications. These data provide number of doses, days,
refills filled, and dosage.
Compliance-For medications, a Medication Possession Ratio (MPR) of 80% is
considered compliant. MPR is the number of days’ supply of medication filled divided
by the number of days of intended treatment.
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Completion-Those who attended at least 60% of WLM classes in one session were
considered completers. This criterion is used by the WLM program to define completion.
For food diaries, 60% per session is complete, also. A participant who turns in 6 out of 10
food diaries in 10 weeks is complete.
Adherence-“The extent to which a person’s behavior-taking medication, following a diet,
and/or executing lifestyle changes, corresponds with agreed recommendations from a
health care provider” (WHO, 2003).
Significance of the Study
The findings of this outcome evaluation can be further utilized to make changes to
WLM and other worksite wellness weight loss programs. The results of this study could
improve programming of future weight loss intervention strategies at the University of
Kentucky (UK) or other worksite wellness programs. If weight loss programs of this
type can be shown to reduce the prescription claims, this could be used as a justification
for the implementation of more onsite weight loss programs. Fewer prescription claims
might mean better health for the individual, lower cost to the employee and the employer.
The health plan costs would also potentially decrease, reducing premiums across the
community. For an organization with a self-funded health plan (like UK), fewer claims
against that health plan means lower premiums for all users of the plan.
If successes are found with the weight loss program, participants might be more
likely to engage in other health promotion programs on the worksite. Successful weight
loss can give participants the motivation they need to make other health behavior changes
through worksite wellness programs such as joining fitness classes, engaging in tobacco
cessation programs, or completing a health screening. Building trusted relationships
with the Health and Wellness staff and other employees through WLM can lend itself to
10

joining other Health and Wellness programs. Success in WLM and fewer prescription
claims can act like a springboard to beginning a healthier lifestyle.
Limitations of the Study
The research study design is a longitudinal pre-experimental pre/post design.
Essentially, this is a pre-test/post-test design using several evaluation methods. There is
no random sampling because there is only one treatment group and no control. Since
there is no control group, the study suffers from some threats to validity. The first threat
is history. Each participant brings in his or her own history that could affect the results.
For example, previous attempts at weight loss, bariatric surgeries, and psychological
factors could have an effect on the results, but are beyond the scope of this study. There
is no way to control this threat. The next threat is testing. Each weekly weigh in could
be on a different scale or conducted by a different tester. This variability isn’t captured.
Finally, instrumentation is a threat. Participants self-report physical activity upon
registration as well as food diary entries throughout the sessions. The result could be an
increase in physical activity beyond what is their norm or better food choices than were
actually consumed.
Additionally, participants are in the study once they begin WLM (starting in
2006). This study will look at each participant over time (no matter the amount of
sessions). So, a limitation will be that some participants will have attended only one
session and some will have multiple sessions of WLM with the understanding that those
who stay in for multiple sessions are likely staying in for weight maintenance. A final
limitation is differing medications. If a participant changes from one category drug to
another in the same category, he/she are still considered on a medication. The influence
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of the drug may be reduced (meaning a decrease in medication in either dosage, amount,
or days’ supply), but it is beyond this study to determine dosage power difference.
The possible threats to external validity are social desirability and expectancy
effect (McKenzie, Neiger, & Smeltzer, 2005). Social desirability is when participants
answer questions or report certain activities because they think that is the answer the
researcher wants to hear. The expectancy effect “is when attitudes projected onto
individuals cause them to act in a certain way” (McKenzie, Neiger, & Smeltzer, 2005, p.
324). One way to control this threat is to repeat the program with a variety of participants
over time. WLM has done this by conducting the program since 2003 with a variety of
participants. The threat of the expectancy effect is reduced by learning to treat everyone
the same. Finally, these results may not be generalizable to all worksite wellness weight
loss programs.
Conclusion
Because worksite wellness programs are an ideal location for weight loss
interventions that are sustained over time thereby increasing the amount of time spent in
the action stage of the TTM, they are thus set up for success. Cost effectiveness is
important to the institution of higher learning, the health plan, and the individual.
However, health outcomes are just as important as cost and are the main focus of this
study. The literature was lacking research in this area when this study was completed.
Therefore, WLM at the University of Kentucky needs to be evaluated to determine the
value of the program in relation to the health outcomes of prescription cessation and
percent body weight lost.
The rest of this dissertation is organized as follows. In the next chapter, the
researcher assessed the literature related to the Transtheoretical model, the costs of
12

behavior change compared to drug treatments, hypertension, diabetes, dyslipidemia, the
socio-economic model, and the costs of worksite wellness. Chapter 3 describes the
research design, a description of population, the WLM program, procedures used to
gather the data, description of measures, and the methods used to analyze the data. The
results in Chapter 4 reveal the effects of each analysis, a brief discussion, and the
limitations of the study. The main findings of the study were: the more classes attended,
the more weight lost; the more food diaries completed, the more weight lost; and after
two sessions of WLM completers were more likely to stop taking their hypertension
medications than non-completers. The discussion summarizes the findings, draws
conclusions, and describes the implications of the study.

13

Chapter 2
Literature Review
The purpose of this review is to discuss the existing literature regarding the
Transtheoretical Model (TTM); worksite wellness weight loss programs using the TTM;
the cost of behavior change compared to drug treatments; weight loss related to
medication reduction in hypertension, dyslipidemia, and diabetes; the Socio-Economic
model which is the framework for the study; and costs of worksite wellness.
Worksite wellness programs often encompass several behavior change programs
targeting many health outcomes. Typical worksite wellness programs target nutrition,
physical activity, tobacco cessation, and stress with outcomes around weight loss, staying
quit, and improving well-being. In many places, the Transtheoretical model serves as the
health promotion model of choice.
Transtheoretical Model
Prochaska’s Transtheoretical Model of behavior change is not only popular, but
useful for many programs including worksite wellness weight loss programming. Weight
Loss Matters (WLM) is loosely based on the Transtheoretical Model (TTM) of behavior
change with the intent of making lifestyle modifications in health behaviors toward
weight loss. The constructs for this model include: stages of change, decisional balance,
self-efficacy, and processes of change (McKenzie, Neiger, & Smeltzer, 2005).
Stages of change. This theory is based on stages of change toward healthy
behaviors. The stages are defined in Table 2.1. For participants in the precontemplation
and contemplation stages, awareness, education, and motivation are the key areas of
action. Awareness, education, and motivation also help move participants toward the
preparation stage. Key actions in preparation might be registering for the program (with
14

fee), attending class, and turning in food diaries. To move participants into action,
attendance and food diary completion are important steps to changing behaviors to lose
weight. Participants in action are making behavior changes to lose weight and are in
maintenance when he or she has been doing so for six months or more. Relapse can
happen at any stage and participants can then work back through the stages using these
action steps above. Termination stage happens when there is no temptation to return to
old habits that counteract weight loss.
Table 2.1
Stages of change
Precontemplation
No plans to make change in the next 6 months
Contemplation
Thinking of making changes in the next 6 months
Preparation
Intends to take action in the next 30 days
Action
Overtly making changes in behavior
Maintenance
Have been making changes for last 6 months
Termination
Have no temptation to return to old habits
Adapted from McKenzie, Neiger, and Smeltzer, 2005
Decisional balance. Decisional balance is simply working through the pros and
cons of changing. By weighing the pros and cons of the changes necessary to lose
weight, people can choose to participate in a wellness program such as Weight Loss
Matters (WLM). The marketing for the program is one way of highlighting the pros of
weight loss. The pros will be different for each person. For example, a pro might be
feeling better, fitting into smaller clothes, or improving a medical condition. The
professional certifications of the program facilitators (registered dietician, licensed
dietician) is also a pro in the decisional balance construct that can persuade participants to
engage in healthy behaviors for weight loss. Another pro is the continued support of the
program with other employee based health and wellness programs.
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Processes of change. Processes of change are consciousness raising, dramatic
relief, self-reevaluation, environmental reevaluation, self-liberation, helping
relationships, counterconditioning, reinforcement management, stimulus control, and
social liberation (McKenzie, et al., 2005). These processes are all activities that people
use to work through the stages and therefore achieve the behavior change. There are ten
processes of change included in the TTM (Glanz, et al., 2008) each of which is described
below and how they are employed in WLM at UK.
Consciousness raising is defined as “finding and learning new facts, ideas, and
tips that support the healthy behavior change” and is addressed through the educational
classes held once per week by the registered dieticians and support of the other
participants (Glanz, Rimer, & Viswanath, 2008, p. 99). The common website used
(OneHub.com) is also a resource for educating the participants, as well as the binders
issued to them at the beginning of the 10 week session. Components or topics of the
education include the exchange system, portion control, reading food labels, and how to
prepare quick meals. Dramatic relief may also be associated with the support and
collaboration of other participants sharing stories and personal emotions. When a person
shares a negative effect in a group of people with common goals, the effect is transferred
to the supporting members thereby causing the person to want to change to avoid that
negative effect.
Self-reevaluation is “realizing that the behavior change is an important part of
one’s identity as a person” and is addressed by the facilitators during the sessions and
also reinforced with the weight loss (Glanz, Rimer, & Viswanath, 2008, p. 99). The
facilitators reiterate how important weight loss is and how it can become part of their
identity. The weight loss itself is a positive reinforcer to self-reevaluation.
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Environmental reevaluation is learning how the behavior impacts a person’s
social and physical circles, either positively or negatively. By realizing the negative
impact of being overweight or obese and the positive impact of weight loss, it often
becomes contagious. That is, the participant encourages others in their social circles to
participate, thereby improving their environment for weight loss. WLM becomes a new
part of the participant’s social circle as it meets regularly for ten weeks. The other
participants become part of the new social grouping. Also, the healthy options on
campus (the physical environment) are pointed out and discussed.
Self-liberation is “making a firm commitment to change” (Glanz, Rimer, &
Viswanath, 2008, p. 99). It is a process that happens both during and after the program.
A participant must decide for him or herself to begin WLM, making some decision for
weight loss. However, continuing the behaviors associated with weight loss typically
comes after time, learning, and experience.
Helping relationships can be found with the facilitators, the other participants, a
participant’s family, or other social circles. Any relationship that supports the behavior
change can be a helping relationship.
Counterconditioning lessons are also part of once a week educational session held
by the facilitators. Counterconditioning is the process of substituting healthier behaviors
for the unhealthy behaviors (Glanz, et al., 2008). The dieticians help to identify mindless
sources of eating and bring a more positive behavior into play to counter any bad eating
habits. Other topics based on counterconditioning are healthy snack choices and healthy
options for eating out.
WLM demonstrates reinforcement management by allowing each participant to
make both short-term and long-term goals, specific to their own behavior. Because every
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person is motivated differently, rewards for healthy behaviors will look different for each
participant. WLM often hosts challenges within each class for one participant to earn a
prize each week. The challenges reflect healthy behaviors that help participants work
toward their goals. Also, the very act of attending WLM week after week helps to
reinforce the ideas and actions to make the behavior change.
Stimulus control is not completely addressed in WLM. The negative cues cannot
be completely removed from life, but positive reinforcements can be learned in place of
negative ones to cue good health behavior. WLM address emotional eating as a topic to
help control mindless eating, eating out of boredom or an emotional response.
Social liberation can only happen if the participant’s social circles are also willing
to make such changes or the social circle itself changes to one that is more supportive.
Being overweight and obese are world-wide problems, and therefore social norms
surrounding weight loss are not easily changed. Because WLM is conducted in small
groups, in a niche culture of a college campus in Kentucky, among university employees,
social liberation can be accomplished to an extent. This is another reason the socioeconomic model was used as the framework for the study. The model takes the different
interacting levels of microsystem, mesosystem, and exosystem into consideration.
These processes of change take time to implement and result in change.
Depending on the participant’s readiness to change, a person may or may not be ready to
move through any of these processes at one time. An employee weight loss program
based on the Transtheoretical model helps people move through the stages of change
using the above-mentioned constructs. Many studies are cited below which support using
the TTM as a basis for worksite wellness weight loss programs.
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TTM in the Workplace
Because American workers spend so much time at work, worksite wellness
programs are an ideal place to implement health promotion programs. Worksites function
as a community all on their own, having a particular culture specific to the workplace.
Individual health behavior changes have been proven to be more effective in the
workplace than organizational interventions (Goldgruber & Ahrens, 2010). However,
interventions aimed at a specific culture can be beneficial, according to Goldgruber and
Ahrens. Their conclusion is that worksite wellness programs must be adapted to the
specific culture or community for which they are intended, but still be aimed at the
individual level. In a study by Renaud et al. (2008) personalized health promotion
programs in the workplace were successful. WLM has been personalized over the
duration of the program to meet the cultural needs of the UK community. Time and
location are one way WLM has been molded over time to fit the UK employee
community. Class times are typical lunch hours and after work hours. Class locations
are on campus near the center of campus and within the healthcare campus of the
University. Another way is to use examples that come from campus or local options
when discussing healthy choices when eating out. Also, challenges and competitions
with WLM are formed around University sports bringing out the “fan” in the participants.
The literature also supports utilizing the Transtheoretical model of behavior
change for worksite wellness weight loss programs. Johnson and colleagues found,
“individualized stage-matched, multiple behavior interventions had significant effects on
progression to Action/Maintenance for healthy eating, exercise, managing emotional
distress, and weight among those most at risk (i.e., those in pre-action) one year post
intervention” (2008, p. 244). This study also showed that weight loss was sustained post19

intervention. This study is similar to WLM in that the main goal is weight loss;
additionally, WLM addresses several health behaviors, as did this study. Like the
research study, WLM also address exercise as a topic and emotional eating as a topic.
Logue et al. (2004) found that the longer a person spends in the action or maintenance
stages of change, the more likely they are to lose weight successfully. Given that WLM
allows participants to repeat the program as many times as desired, this can aid in weight
loss and maintenance of the health behavior, thereby being successful. As Logue et al.
(2004) pointed out, the longer people are actively losing weight or maintaining their
weight; the more successful they are with long term weight loss. DiNoia and Prochaska
(2010) examined the decisional balance relationship to stages of change for dietary
behaviors. They discovered during precontemplation, the cons are higher than the pros
and during action and maintenance, the reverse is true. This is reinforced in WLM, with
maintenance and then termination as the goal. Participants are more likely to keep the
weight off and change their behaviors if they accept more pros than cons. O’Connell and
Velicer conducted two studies where decisional balance pro/con decisions demonstrated a
successful behavior change of weight loss (O’Connell & Velicer, 1988). Finally,
O’Connell and Velicer (1988) added that the move from contemplation to action may be
the time most important in terms of decisional balance. TTM is highly important in
changing health behaviors related to weight loss and control, particularly the constructs
of decisional balance and stages of change (O’Connell and Velicer, 1988). WLM has
employed the TTM in the UK worksite wellness programming to promote behavior
change.

20

Behavior Change Compared to Drug Treatments
Avenell et al. (2004a) concluded that low-fat diets and exercise interventions in
individuals at risk of obesity-related illness, such as diabetes, are of comparable cost to
drug treatments. Their statement is supported by other literature as well, indirectly.
Though Avenell et al. (2004a) reported comparable costs of drug treatment versus
lifestyle modifications; many studies reported cost savings through weight loss.
Specifically, in a study by Gustafson et al.(2009), cost effectiveness was evaluated by life
years gained compared to the cost of conducting the weight loss program. “The WeightWise intervention cost of $61 per kg lost ($27.72/lb) also compares favorably to costs
reported by other studies, …” (Gustafson et al., 2009, p. 393). The life years gained were
scaled to all costs, indicating the Weight-Wise intervention was effective. In a study by
Wang et al.(2006), body mass index (BMI) was reviewed as a linear relationship with
cost when BMI is 25 or higher. “Within the BMI range of 25 to 45 kg/m2, medical costs
and pharmaceutical costs increased $119.7 (4%) and $82.6 (7%) per BMI unit,
respectively, adjusted for age and sex” (Wang et al., 2006, p. 668). Because of the linear
relationship, the dollar amounts can also be thought of in the reverse. Not only is higher
BMI associated with higher cost, lower BMI (in the normal range) should have lower
costs. A longitudinal study was performed by Finkelstein et al. (2009) on weight loss and
the associated medical costs. They found that pharmacy expenditures were significantly
decreased in the group that lost weight as compared to the control group. Emphasis in
this study was placed on the long-term weight loss of employees and not simply short
term to see the greatest cost savings. Hughes, Girolami, Cheadle, Harris, and Patrick
(2007) also reviewed the cost savings of weight loss in worksite wellness programs by
reviewing prescription drug claims of three Fortune 500 companies (N = 512). “The
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number of participants taking prescription drugs decreased from 48 to 39 (19%) between
baseline and 1-year post intervention in a subgroup of 61 participants” (Hughes et al.,
2007, p. 1215). After applying a current (to the time) annual drug cost average, they
estimated that this could result in a $2382 decrease per participant. This is about a 50%
savings (Hughes et al., 2007). Though these results are positive, such a small sample size
could be limiting. Carls, Goetzl, Henke, Bruo, Isaac, and McHugh (2011) conducted a
longitudinal study of the Johnson & Johnson Corporation and the impact of weight gain
or loss and health care costs. This study had major significance as it was one of the first
to use both longitudinal data and find significant savings with weight loss. They found
“Employees who added weight risk (moved from BMI < 30 kg/m2 to BMI > 30 kg/m2)
increased their average annual medical costs to $1267, about $982 (95%CI: 255-$1710)
more than employees who remained at lower risk, whose cost increased an average of
$285 each year” (Carls et al., 2011, p. 11). In addition, those who gained weight risk also
increased their health care costs by 9.9% (Carls et al., 2011).
Part of the picture of drug costs includes compliance and adherence to the
prescribed therapies. In 2001, the World Health Organization (WHO) launched a global
initiative to study and make recommendations for long-term adherence. Their work
group chose ‘adherence’ as opposed to ‘compliance’ to better reflect the patient’s
agreement with the health care provider’s recommendations (WHO, 2003). In addition,
adherence is not only to drugs, but any health-related behavior recommended by the
health care provider. This might include taking medication, following a diet, or
implementing lifestyle changes. For developed countries, the adherence rate of lifestyle
behavior changes averages 50% and is lower in developing countries (WHO, 2003, p.13).
Separately, compliance is a term utilized by the pharmaceutical industry and is a
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calculation of number of days’ supply of medication filled divided by the number of days
intended treatment (Lucy Wells, personal communication, July 23, 2014).
Furthermore, the WHO suggests greater incidence of non-adherence in asthma,
hypertension, diabetes, and HIV/AIDS. In diabetes, specifically, adherence refers to
taking medications, self-monitoring of blood glucose, dietary restrictions, regular foot
care, and ophthalmic exams. Not only does non-adherence negatively affect the patient,
but also societal and economic costs, as well. The worksite would also be affected by the
above.
Hypertension
Hypertension or elevated blood pressure (BP) is specifically linked to overweight
and obesity. A review study by Johnson et al., (2006) found that three specific
interventions demonstrated improvement in medication adherence. “Although drug
therapy can effectively lower BP and prevent stroke and heart disease, it does not address
the underlying causes of elevated BP, including obesity, unhealthy dietary habits, and
limited physical activity” (Funk, et al., 2008, p. 272). Therefore, compliance to
pharmacotherapy may not be the answer to helping cure hypertension. Lifestyle
modifications have shown better rates of adherence thereby decreasing hypertension.
“Weight-loss incorporating lifestyle modifications have been found to decrease resting
BP [15], and [they] found that 4.3-kg loss in weight (4.6%) was sufficient to significantly
decrease resting SBP by 3 mmHg” (Torres & Nowson, 2007, Discussion, para 1).
Lifestyle modifications can include increasing healthy dietary habits and physical
activity, as well as decreasing stress and alcohol intake.

“These lifestyle

modifications are recommended in non-hypertensive individuals with above –optimal BP.
For individuals taking BP medication, lifestyle modification is recommended as
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adjunctive therapy to lower BP” (Appel et al., 2003, p. 2004). These also happen to be
the same lifestyle modifications recommended to decrease risk of diabetes and cancer.
Other studies have shown similar results. Miller et al. (2002) noted that
comprehensive lifestyle changes can be powerful interventions for those who use blood
pressure medication. In a weight loss study, Horvath et al. (2008) discovered those who
lost weight needed less medication than the non-weight loss groups. Not only did
medication need decrease, other studies found a decrease in BP with adjunctive therapies.
Torress and Nowson (2007) noted a 2.8 + 1.4 mmHg decrease in systolic blood pressure
with weight loss. Alcohol restriction and relaxation therapy proved to lower BP
(Blumenthal et al., 2002). Appel et al. (2003) and Blumenthanl et al. (2002)
demonstrated that when lifestyle modifications are combined there is a greater and more
significant effect than one intervention alone.
Diabetes
Several studies have demonstrated lifestyle modifications can positively affect
glycemic control, perhaps even better than pharmacological therapy. However, there has
been little evidence to show a removal of medication using lifestyle modifications alone.
Lifestyle modifications include behaviors such as weight loss, physical activity, and
healthier food choices. Weight loss is the key lifestyle intervention most greatly
associated with decreasing risk and key markers for diabetes. A recent study reported
“In overweight and obese individuals with type 2 diabetes, weight loss is associated with
improvements in risk factors” (Horton, Silberman, Davis, & Berria, 2010, p. 1759).
“Changes in body weight were significantly associated with reductions in A1C” (Horton
et al., 2010, p. 1761). A person’s risk of diabetes increases 9% with every 1 kg of weight
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gain, according to Mokdad et al. (2000). Again, (Hamman et al. (2006)) suggested
weight loss had more of an impact on diabetes than diet or physical activity.
According to studies by Aucott (2008); Delhanty (2002); Elhayany, Lustman,
Abel, Attal-Singer, and Vinker (2010); Fujioka (2010), Albu et al. (2010); Eakin et al.
(2010); and Kempf, Kruse, and Martin (2010), the benefits of weight loss on diabetes are
reduction of risk and specific markers. Albu et al. (2010) studied metabolic changes in
type 2 diabetics after 1 year of diet and exercise interventions and found significant
improvements in insulin sensitivity, fasting glucose, and circulating free fatty acids
among other results. Delahanty (2002) made the point that even a small amount of
weight loss can show improvements in diabetic markers. Elhayanay and colleagues
(2010) studied an Israeli population and repeated the same results: that weight loss
improves type 2 diabetes. “In these studies some weight loss (3-5 kg) was associated
with a reduced risk of developing diabetes when compared with the weight-stable group,
by >10% (upper CI)” (Aucott, 2008, p. 55-56.) Kempf et al.(2010) and colleagues
reiterated the effectiveness of lifestyle modifications for type 2 diabetes. Participants
who completed their study had a significant reduction in weight, BMI, waist
circumference, HbA1c, systolic and diastolic blood pressure, and LDL cholesterol. In
addition, depression was decreased in this group, as well. After studying the correlation
between weight loss and HbA1c, Kempf et al. found “a weight loss of 1 kg was
associated with a mean reduction of 0.05% HbA1c” (2010, p. 550).
Aucott went on to say “evidence is now emerging that lifestyle interventions are,
in the long term, more effective in reducing the risk of developing diabetes than using the
diabetes mellitus-specific drug Metformin” (2008, p. 56). In this systematic review, the
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conclusion is that diet, physical activity, and behavior therapy are effective for long term
intentional weight loss.
Dyslipidemia
The risk factors that contribute to dyslipidemia include: genetics, ageing, diabetes,
smoking, sedentary lifestyle, poor dietary habits, and overweight or obesity (CDC, 2010).
Again, obesity is the major risk factor in dylipidemia as previously shown in the other
two conditions. “The dyslipidemia of obesity is typically associated with insulin
resistance, including higher concentrations of fasting triglycerides and lower
concentrations of HDL cholesterol” (Hernandez et al., 2010, p. 578.)
To correct dyslipidemia in persons with metabolic syndrome, weight loss is the
best first choice (Grundy et al., 2006). Harman, Leeds, and Griffin (2008) compared an
energy restricted diet plus two eggs per day compared to the same energy restricted diet
and found that both groups had a decrease in LDL cholesterol. They attributed this
decrease to weight loss and suggested an increase in LDL was counter-effected by the
weight loss. Pooblan et al. (2007) studied long term outcomes in the obese and found a
linear relationship between weight loss and cholesterol. They went on to say, “this
suggests that every 10 kg of weight loss may result in an expected drop of 0.23 mmol/L
in cholesterol for a person with obesity” (Pooblan, 2007, p. 49). Santosa, Demonty,
Lichtenstein, and Jones (2007) found cholesterol decreased with weight loss in women
due to changes in cholesterol metabolism. Weight loss was associated with lower LDL
cholesterol and increases in HDL or good cholesterol. Gustafson reported the women in
the study improved their weight, systolic blood pressure, BMI, and YLL reduction (years
of life lost) (2009). She added that those who attended more sessions had greater
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improvements, making the case for attendance compliance (a majority of classes) among
weight loss individuals.
The evidence is that weight loss improved cholesterol levels, among other
measurements, over time. In 2004, Pooblan and colleagues showed that weight loss does
in fact have long term effects on cholesterol. Even more recently, Meckling and Sherfey
found that total cholesterol was decreased by a controlled diet and exercise as well as a
high protein diet. Triglycerides were decreased in the high protein plus exercise group.
All four groups (control, control plus exercise, high protein, and high protein plus
exercise) lost weight, improved BMI, BP, and waist and hip circumference, indicating the
efficacy of weight loss and exercise on cholesterol (2007). Matsuo et al. (2010) found
weight loss improved many metabolic factors. However, the significant finding was that
HDL cholesterol improved after two years of maintaining lost visceral abdominal fat
levels. The mean values for triglycerides, glucose, and total cholesterol/ HDL ratio were
all lower after two years, as well as with weight loss. “After 4 mo of active weight loss,
the CHO group had significant reductions in TC, LDL-C, and TAG” (Layman et al.,
2009, p. 519); however, these reductions were not sustained in the long term (12 mo).
“After 4 mo, the PRO diet resulted in lower TAG, increased HDL-C, and improved
TC:HDL-C and TAG:HDL-C ratios”(Layman et al., 2009, p. 519). These changes were
sustained at 12 months. The studies just described all indicate that weight loss impacts
cholesterol positively. “In two studies adding exercise to diet was associated with
beneficial effects at 12 months for HDL cholesterol (change to 0.1 mmol L-1, 95% CI,
0.06 to 0.14 mmol L-1) and TGs (change -0.18 mmol L-1, 95% CI, -0.31 to -0.06 mmol
L-1)”. (Avenell et al., 2004, p. 308-309).
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Socio-economic Model
The Socio-Economic Model or ecological model was first introduced as a systems
theory model by Kurt Lewin in 1951 to explain behavior (Glanz, Rimer, & Viswanath,
2008). It has been built upon and adapted by several authors including Barker in 1968,
Moos in 1980, Bronfenbrenner in 1979, and Glass and McAtee in 2006 (Glanz et al.,
2008). The theory has been further utilized to guide behavioral interventions by early
authors such as Skinner and Bandura to others as recently as 2005. Bronfenbrenner
(1979) breaks the theory down into environmental systems. The microsystem includes
interactions between family members and work groups. The mesosystem is the physical
settings of family, work, and school. The exosystem is the larger systems including
politics, organizations, and culture.
The premise of the model is that all levels of an environment work together to
influence both the person and reciprocally, the environment, as noted by the term
reciprocal determinism. “The ultimate purpose of ecological models of health behavior is
to inform the development of comprehensive intervention approaches that can
systematically target mechanisms of change at several levels of influence” (Glans, Rimer,
& Viswanath, 2008, p. 466). Glanz and colleagues (2008) explained there are four core
principles of the ecological model: multiple influences on specific health behaviors
(intrapersonal, interpersonal, organizational, community, and policy levels); these
influences interact across levels; the model should be behavior specific (using the most
relevant influences at each level); and interventions that are multi-level are the most
effective for behavior change. Simply stated, just because a person is educated for a
health behavior change does not mean that person will make a change. In order for
health behavior change to occur, the total environment must support the healthy behavior.
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All the levels of influence must change. For example, intrapersonal-food education,
interpersonal-support network encouragement, community-institution supported changes,
and policy-broader policy change to support healthy eating would be needed to affect
healthy eating.
The ecological model has been widely used by such entities as the World Health
Organization’s Global Strategy on Diet, Physical Activity and Health (World Health
Organization, 2011) and Healthy People 2020 (U.S. Department of Health & Human
Services, 2010). The model has been used in tobacco cessation efforts with success and
researchers have high hopes of applying it to the obesity epidemic “by improving
environments and policies that drive physical activity and nutrition behaviors” (Glanz,
Rimber, & Viswanath, 2008, p. 479). The obvious strength of the model is its use of
many influences and across levels making interventions at several levels more effective.
The weakness of the model is not being specific about which influences might have the
most effect on the behavior change (Glanz et al., 2008).
A more recent study by Karlsen, Sohagen, and Hjelmesaeth (2013) suggests using
a “bio-psycho-social model” to study predictor variables on weight loss. They strongly
advise using a model that will take all of the above levels of interaction into consideration
stating “In a real life context, as in a weight loss program, individual physiological and
psychological factors, often genetically influenced interact with social and environmental
factors, giving a multitude of individual responses to both the magnitude and rate of
weight changes” (Karlsen, Sohagen & Hjelmesaeth, 2013, p. 2). This is a good
description of how the ecological model works.
As related to WLM, the ecological model works within the context of UK. The
multiple influences on weight loss might include: the particular WLM class, the person’s
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work group and family/friends network, the institution’s culture, the available food on
campus, the socio-economic status (SES) of the person, and the physical activity avenues
available on campus and in the person’s network. All of these influences interact across
levels; meaning the food available on campus is influenced by the UK culture and the UK
culture is influenced by the employees and students of the University and the employees
and students are influenced by their family and friends network. There are multiple
levels of interaction. The specific behavior is weight loss and there can be changes at
many of these levels to affect weight loss.
On the microsystem level, there are several variables: age, sex, BMI, and SES.
On the mesosystem level, the variables include: family, friends, small groups (work
groups), and the specific WLM group. The exosystem includes UK culture, UK as an
organization, and UK policy. The University of Kentucky 2009-2014 strategic plan
comes from the exosystem level. However, the strategic plan influences the resources
and supports offered on the other levels. “The five goals of this Strategic Plan identify the
principal areas of activity in which the talents and resources of the University will be
invested over the next five years. Under each goal are several objectives, strategies, and
metrics that make specific the intentions of the University of Kentucky”
(http://www.uky.edu/Provost/strategic_planning/plan.htm). There are several ongoing
supports and resources that are a result of the group programs and strategic plan. All of
these systems: microsystem, mesosystem, and exosystem, interact with each other. There
are resources and supports that come from each system level and interact upon one
another. Variables at each level could not be tested for the scope of this research. Figure
2.1 is a diagram of the Socio-economic model as applied to WLM at UK.
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Figure 2.1

Ecological model in the literature. McLeroy, Bibeau, Steckler, and Glanz
(1988) discussed the ecological model and interventions on both the individual and social
level for health promotion programming. They suggested five levels of an ecological
model: intrapersonal, interpersonal, institutional, community, and public policy
(McLeroy, Bibeau, Steckler, & Glanz, 1988). Intrapersonal factors include participant
information such as knowledge, attitude, behavior, self-concept, and developmental
history. Interpersonal factors are formal and informal social network, support systems
such as family, work, and friends. Institutional factors include formal and informal rules
and regulations for operation. Community factors are relationships among organizations,
institutions, and networks within those communities. Public policy includes local, state,
and national laws and policies (McLeroy et al., 1988).
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Baranowski, Cullen, Nicklas, Thompson, and Baranowski (2003) reviewed
several research studies utilizing the ecological or social ecological model and suggested
incorporating cognitive variables into the model to address cues to action, facilitation of
healthy options by only having certain facilities or food choices available, inhibiting or
prohibiting a behavior by controlling availability or access, and altering the attractiveness
of the alternatives. After reviewing the most popular health behavior change models,
they stated “behavior-and ecology-based problems require behavior-and ecology-based
solutions” (2003, p. 38S). Therefore, they suggested further research to correlate
causative variables and then focused on procedures that would manipulate the variables
in order to be the most effective against obesity. In summary, these authors (2003)
suggested changing both the environment and individual characteristics for the most
positive results of behavior change.
An example of the above idea is by Karlsen, Sohagen, and Hjelmesaeth (2013)
who found several variables that had direct influence of weight loss at 1 year post
intervention: weight lost at 12 weeks, age, mental HRQL (emotional quality of life), and
employment status. Using these three variables, they found a direct influence on weight
loss.
Costs of Worksite Wellness
Van Dongen and colleagues (2011) completed a systematic review of 18 studies
on the financial return on investment of worksite health promotion programs targeting
nutrition and physical activity. They assessed ROI, net benefits, and benefit cost ratio
(BCR). Return was estimated in terms of absenteeism and medical benefits. Net benefits
were calculated as benefits (difference of intervention and control groups monetized
outcome measures) minus costs (difference in program costs between intervention and
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control groups). BCR was calculated as benefits divided by costs. ROI was calculated as
benefits minus costs divided by costs and multiplied by 100 for a percentage. The
researchers made all values in terms of US dollars as of 2010 by standardizing to
consumer price indices and purchasing power parities (van Dongen, 2011). In the 18
studies, interventions included assessment (including self-assessments),
educational/informational components, behavioral, exercise, environmental and/or an
incentive component that lasted from six months to five years. “The financial return was
positive in 14 out of 21 interventions” (van Dongen et al., 2011, p. 1043). The
differences were between randomized control trials and non-randomized studies, where
the randomized control trials had the most promising results. Therefore, worksite health
promotion programs aimed at improving nutrition and physical activity were found to
have a positive return on investment during the first years of implementation as well as
reducing employee health care costs (van Dongen et al., 2011). They also noted the
intangible benefits go beyond the financial benefits to also increase worker satisfaction
and improve reputation (van Dongen et al., 2011).
In summary, the implications of weight loss interventions in the worksite are
many: improved morale, decreased presenteeism and absenteeism, and improved health
risk and health care costs to both the employee and the employer. Regarding employer
medical costs for employees, there are several conditions or behaviors that are highly
prevalent and therefore have high associated costs. Table 2.2 below displays data from
the American Heart Association (2009) indicating prevalence, medical costs, and
performance loss associated with various heath conditions/behaviors.
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Table 2.2
Prevalence Data and Associated Medical Costs and Performance Loss Costs

Condition/Behavior Prevalence

HBP

High (1 in 3 adults
have elevated BP)

Cholesterol

High (27% of adults
have cholesterol of
240 or above)

Very High (58% of
employees are
Exercise-general
sedentary)
Nutrition
Very High (80% of
adults consume too
much fat; 1/3 are
overweight)
Adapted from the AHA (2009)

Direct medical costs
Very high ($101
billion/yr across the
nation in estimated
costs)
Very High ($60 billion
in medical costs related
to elevated cholesterol)
Potentially very high
(linked to 23% of deaths
from CHD, stroke,
colorectal cancer,
diabetes)
Potentially very high
(related to 5 conditions
costing $146 billion)

Performance
loss

Potentially
high

Unknown

Unknown
Unknown

A healthy employee costs less than an employee with health conditions. “The
truth is healthy employees not only cost less in medical care, they also are more
functional at work, absent less often, experience fewer injuries, and arrive back on the job
more quickly after they do get injured” (Lynch, 2002, p. 17) (Thompson et al., 2005). It
is not all about the bottom line of cost. Employees are valuable assets to companies,
regardless of their ‘price tag’.
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Chapter 3
Methods
This chapter includes the methodology by which the study was conducted.
Included are research design, description of the population and participants, how the data
were collected, description of measures, description of the program, data coding and
reorganization, statistical analysis, and categorization.
Research Design
The research design was a quasi-experimental, longitudinal design in which the
same participants were followed over time, measuring the same variables at different
intervals. Data were collected post-hoc from historical records kept by UK Health and
Wellness staff and UK Healthcare. Prescription claims data were gathered 12 months
prior to program participation, six months post program, and 12 months post program.
This longitudinal design was particularly appropriate given the length of time it takes to
change health behaviors or to see a decline in medication use (Finkelstein et al. 2009,
Hughes et al., 2007).
Description of population
The population included 14,000 University of Kentucky employees from 2006 to
2011. The University of Kentucky is a public institution in the city of Lexington, and
Commonwealth of Kentucky. The setting for Weight Loss Matters (WLM) was the
University of Kentucky campus.
There are several factors within the University that contribute to a distinctive
culture. Due to so many different subgroups of employees, each one has unique
elements. The two main categories of participants were faculty and staff. Staff persons
typically worked during the day with regular office hours. There are several subgroups of
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staff, including full-time, part-time, administrative, support staff, and skilled workers.
The subgroups of faculty included: full-time, adjunct, part-time, and lecturers. The
faculty had different schedules than staff persons. Where a staff person may work the
typical schedule with a one hour lunch break around noon, faculty persons varied greatly
with no set hours, thereby, making programming or access to programming difficult.
Typically, faculty were more educated, had higher incomes, and therefore higher
socioeconomic status (SES) than a staff person. A higher SES correlates with increased
health and conversely, lower SES correlates with decreased health (REPORT,
heathcare.gov). Therefore, faculty were potentially healthier, yet with a more difficult
programming schedule in a culture different from the rest of the UK community. The
staff had the widest range of socio-economic possibilities from top level administration to
skilled technical workers. All of these factors make for a melting pot of employees
creating a challenging environment to practice worksite wellness.
WLM Program Goals and Objectives
Goals are overarching expectations of what a program will accomplish.
According to McKenzie, Neiger, and Smeltzer (2005, p. 129), a goal is “much more
encompassing, or global, written to include all aspects or components of a program,
provides overall direction for a program, more general in nature, usually takes longer to
complete, does not have a deadline, usually is not observed, but rather must be inferred
because it includes words like evaluate, know, improve, and understand, is often not
measurable in exact terms.” The overall goal of Weight Loss Matters was for participants
to lose weight through behavioral lifestyle changes learned through educational sessions.
Objectives are “more precise and represent smaller steps than program goals-steps
that, if completed, will lead to reaching the program goal(s)” (McKenzie et al., 2005, p.
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130). Objectives are broken into hierarchical levels, becoming more specific with each
level (McKenzie et al., 2005).
Learning objectives are the first level and focus on steps given to the participants
to achieve weight loss. There were three main learning objectives for the student: (1) to
exhibit nutritional knowledge by food choices reflected on the food diaries, (2) to identify
cognitive or mental barriers weekly as smaller goals, and (3) to learn the Exchange
system as reflected in their food choices and recording of food diaries all turned in on a
weekly basis. These objectives were assessed by the registered dieticians (RDs) on a
weekly basis. Sessions included information on how to read a food label, proper portion
sizes, mindless or emotional reasons for eating, the importance of exercise, eating smart
while eating out, and easy meals. These topics help satisfy the first learning objective.
These were the steps given to the participants to make a lifestyle change and lose weight.
Behavioral objectives are action oriented. There were four behavioral objectives
for WLM: by the end of WLM, participants will be able to apply the nutritional
information to their lifestyle; utilize a support network through discussions; participate in
weigh-ins for accountability; and to self-monitor using food diaries.
Outcome objectives “are the ultimate objectives of a program and are aimed at
changes in health status, social benefits, risk factors, or quality of life” (McKenzie et al.,
2005, p. 132). Since the overarching goal of WLM was for participants to make lifestyle
changes through weight loss, then the outcome objectives included weight loss,
improvement in health literacy/education, maintenance of weight loss, reduction in risk
for chronic diseases, decreased morbidity and mortality, and increased quality of life.
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Program Description
The Weight Loss Matters (WLM) program was a 10-week weight loss program
designed for University of Kentucky (UK) employees, retirees, spouses, and sponsored
dependents. WLM was designed by the UK Health & Wellness program dietician in
2003. Participants were charged a $50 fee; however, they could re-enroll in another
session of 10-week classes for free as long as they were meeting their weight loss goals
and felt the program continued to help them. If the participant did not meet his/her goals
or dropped out and returned, he/she were only charged $25. However, by turning in eight
out of 10 food diaries, a participant could have the $25 fee waived.
The program was designed for in-person delivery and offered at set times during
the year in 10-week increments. Classes were offered three times per week in different
campus locations. Classes were held on weekdays with at least one class at lunch time
and one class in the evening, all covering the same topic. An online class was offered
every Wednesday from 12:10-12:50PM; however these data were not included in the
study due to lack of data for this class. Participants registered for one of the in-person
classes, but could attend any class if they missed the meeting time of the one in which
they registered. If a participant had to miss a class, he or she could either come to one of
the other classes offered or continue in WLM for additional cycles. Weekly class topics
included, but were not limited to: decoding food labels, portion distortion, mindless
eating, physical activity, eating out, easy meals, weekend warriors, emotional eating, and
excuses. Food and exercise diaries were kept by participants and turned in weekly for
feedback from a Registered Dietician (RD) on a voluntary basis. Also, each participant
completed a weekly weigh-in by a trained staff person. Physical activity was encouraged,
but not required.
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In order to help participants with maintenance of the healthy behavior of weight
loss; the program facilitators used several strategies. First, the participants set their own
weight loss goals. Research into WLM by Dr. Maura Scott in UK’s Gatton College of
Business and Economics revealed that participants viewed their progress more positively
if they chose a weight range to lose instead of a number of pounds (personal
communication, 2010). Therefore, WLM asked participants to set weight range goals.
Also, the program was self-paced which allowed stronger self-efficacy and therefore
aided in maintenance. For example, one participant could lose one pound and feel
successful while the same week, another participant could lose three pounds and be just
as successful. Finally, the strategies taught by the RDs were behavior-change based
lifestyle modifications. The support found in the group setting also aided in strategizing
for barriers and issues; thus, aiding in maintenance. If there were participants who
completed three sessions in a row (three ten-week sessions) they were recognized as
“Veterans”. They were asked to share their stories, give advice, and were featured on the
One Hub website for all WLM participants to recognize.
Relapse prevention was addressed on a case by case basis. Because the classes
were in person, the RDs were in touch with every participant. Also, the participants were
asked to set weekly goals that were not weight related to help stay on track and encourage
further modifications. For example, a non-weight related goal could be to sleep eight
hours three nights per week. In the event a participant were absent two weeks in a row
with no other communication, the RDs contacted that person to invite him/her back and
make it easy to get re-involved. In addition, as previously mentioned, a participant could
stay in WLM for a second (or more) 10 week session for free if he or she continued to
meet his or her goal.
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This program design demonstrates the Transtheoretical Model approach used in
WLM. Moving through the stages of change by weighing pros and cons, understanding a
participants own self-efficacy, and using the processes of change previously described,
helps participants to change their behaviors related to weight loss.
Participants
For the purpose of this research, only UK employees who were on a UK health
plan were included. The sample included employees who participated in WLM for at
least one session between June 2006 and December 2011 for whom there were data.
Online WLM participants were not included due to lack of data. Retirees, spouses, and
sponsored dependents were not included so the results would be more comparable to
other worksite wellness program evaluations. There were 591 unique participants
included in this study. Participants were either full time or part time employees of the
University between June 2006 and December 2011.
Data collection-Records from WLM
WLM records from June 2006 to December 2011 were examined for information
on UK employees who were on a UK Health Plan and completed an in-person WLM
class. These paper records were kept by WLM staff in locked file cabinets or in
password protected Access database. Permission to access these records was obtained
from the Health and Wellness Program Manager. Institutional Review Board approval
was obtained prior to data records being accessed.
Participants were asked to complete a registration form that included several
variables: sex, date of birth, current height, weight, health concerns, previous attempts at
weight loss, and physical activity level (see Appendix B). Then, throughout the ten
weeks, the facilitators gathered other data. Out of that data pool, this study utilized
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weekly weigh-in weight measured in pounds by the program facilitators as well as food
diary compliance (see appendices C and D). For this study, food diary compliance was
defined as six diaries turned in out of the possible ten-week period. A weekly diary was
considered complete if it held three days or more of reported food intake. Likewise,
attendance completion was defined as participants having attended six classes out of ten.
Also, the facilitators collected final measurements of height (self-reported) and weight
(measured). All data were kept confidential by password protection, encryption, and
using secure servers.
Data collection -Records from UK Health plan
The prescription claims data were collected from the UK health plan claims
database by the UK Associate Director for Mental Health Data Management (second
researcher) at the start date of WLM, 12 months prior to WLM, six months post WLM,
and 12 months post WLM for each participant for each session. Prior to the second
researcher obtaining the records, IRB approval was obtained. The primary investigator
supplied the UK Associate Director for Mental Health Data Management the data for all
participants for all sessions to access the prescription claims, before and after WLM,
including social security numbers (a unique identifier). From the prescription claims list,
the primary investigator worked with a UK Pharmacist to gather a list of drugs that fell
into three categories: hypertension, cholesterol, and diabetes (see Table 3.1).
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Table 3.1
Drugs used
CATEGORY
ID
317
316
173
252
241
174
216
372
314
214
371
293
373
215
282
309
458
213
271
42
56
44
43
55
48
274
51
275
155
342
156
53

CATEGORY_NAME
antihyperlipidemic combinations
cholesterol absorption inhibitors
HMG-CoA reductase inhibitors
bile acid sequestrants
fibric acid derivatives
miscellaneous antihyperlipidemic agents
alpha-glucosidase inhibitors
amylin analogs
antidiabetic combinations
biguanides
dipeptidyl peptidase 4 inhibitors
glucose elevating agents
incretin mimetics
insulin
meglitinides
miscellaneous antidiabetic agents
SGLT-2 inhibitors
sulfonylureas
thiazolidinediones
angiotensin converting enzyme inhibitors
angiotensin II inhibitors
antiadrenergic agents, centrally acting
antiadrenergic agents, peripherally acting
antihypertensive combinations
calcium channel blocking agents
cardioselective beta blockers
miscellaneous cardiovascular agents
non-cardioselective beta blockers
potassium-sparing diuretics
renin inhibitors
thiazide and thiazide-like diuretics
vasodilators

Indication
Cholesterol
Cholesterol
Cholesterol
Cholesterol/Lipids
Cholesterol/Lipids
Cholesterol/Lipids
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension
Hypertension

Note: For a more detailed table of specific drugs, their purpose, use, and side effects, see
Appendix D.
The second researcher then matched the person with the claims, de-identified the
data, and passed to the primary investigator. Data analysis was conducted by the primary
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researcher. All data were encrypted by the secondary researcher. In other words, the
data were translated into another form before being passed to the primary investigator so
as not to be able to trace the identity of the participants.
Description of Measures
The following measures were collected by the WLM program: attendance,
physical activity, food diary compliance, goal, height, and weight. These measures were
collected via the intake form, food diaries turned in, and weekly weigh in sheets. Body
Mass Index (BMI) was calculated as weight in kilograms/height in meters2. Weight loss
was calculated for each session as starting weight-ending weight. Percent body weight
lost was calculated for each session as weight lost/starting body weight.
Intake form
A “completer” attended six out of 10 classes. This number was determined
because it is the majority of classes, demonstrated by similar research to be the minimum
effective dose, and is what the staff of WLM determined a completer for program
purposes (Samuel-Hodge et al, 2009). Physical activity was measured by self-report in
number of days per week and minutes per day at the intake. Physical activity questions
included “Are you physically active?”, “Number of days per week you are active,”
“Duration of activity,” “Type of activity” (i.e. walking, aerobics, biking, weight training,
etc). These questions are similar to the 2011 Behavioral Risk Factor Surveillance System
(BRFSS) in asking frequency, duration, and type of activity. Participants were asked to
provide a goal using open text response. These responses were categorized into themes:
weight loss, maintain, feel better, doctor’s suggestion, or any combination of these.
Starting height was self-reported at the start and used throughout.
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Food diaries
Food diaries were measured by quantity, one for each week of participation
possible, not the content of the food diaries. Participants were asked to record all food
and beverages each day for a week, categorizing them into food groups based on the
Exchange system. The diabetic exchange system is a way to organize foods based on the
amount of carbohydrate, fat, protein, and calories they contain. There are three main
categories: carbohydrate group, meat/meat substitute group, and fat group. All choices in
each category on the list is equal and can be exchanged for any other on the list
(http://www.uaex.edu/publications/pdf/fshed-86.pdf . The registered dieticians then
provided feedback each week to the participants. Food diaries were encouraged each
week, but not mandatory for participation in the program. (See appendices).
Weekly weigh in
Weight was measured and recorded each week by trained Health and Wellness
staff using calibrated digital scales. This weekly weigh in was also used to determine
attendance on a weekly basis.
Health plan measures
Prescription data were collected from the University health plan database and
included days’ supply, quantity, and dose for the three conditions: hypertension, diabetes,
and dyslipidemia starting twelve months prior to participation, six month post
participation, and 12 months post participation. First, the secondary researcher pulled all
prescription claim data for participants in these date ranges. From these, the primary
investigator worked with the UK Pharmacist to determine which drugs were used for
hypertension, cholesterol, or dyslipidemia. Then, the secondary researcher only provided
the drugs for the three conditions for each person at each time frame. By having each
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medication for each participant at each time frame, this allowed testing of whether or not
participants ceased taking medications at different intervals.
Data Coding and Reorganization
The participant’s sex was coded as male (0) or female (1). Sessions completed,
number of classes per session, starting, and ending weight for each class were entered.
The start and end dates of each session were also recorded. This allowed the data to be
changed into subsets on a per session format. Self-report physical activity was coded as
yes (1) or no (0); and further described in minimum days per week, maximum days per
week, minimum minutes per day, and maximum minutes per day. Height was entered in
inches. The prescription data were entered as specific prescriptions 12 months prior to
start date in milligrams of dose and days’ supply of dose and these same measures again
at six months and 12 months from start date. Previous weight loss attempted could be no
(0) or yes (1). The participant’s goals were categorized as: weight loss (0), maintain (1),
look better/feel better (2), doctor’s suggestion/medical reason (3), combination of 0 and 1
(4), combination of 0 and 2 (5), combination of 1 and 2 (6), and combination of 3 and 0
(7). These were the combinations included because these were the combinations present.
Missing data (N = 3) were corrected where possible by checking ranges and
correcting key stroke errors but when not possible, they were coded as missing (N = 1).
For medications that had two drugs in one medication which had two dosages (one for
each drug), the drug names and dosages were split into separate columns. For example:
Hydrochlorothiazide-Triamterene with a dosage of 25-37.5 mg was split into
Hydrochlorothiazide for 25 mg and Triamterene for 37.5 mg. This was in consultation
with the UK Pharmacist to better understand each medication. For goals 0-7, they were
changed to binary codes either 0 (not present) or 1 (present) for each goal. The same
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coding was done for medication category. For each category of medication, they were
given a 1 for yes and 0 for no. In order to move all the data into short form, the rows were
given either 0 or 1 for presence of each health condition at each time frame. [In order to
get each individual’s data on one line, the data were manipulated into data sets.] Next, the
records were concatenated to put all of each person’s individual medications into
sessions. This left the dataset in a “per session” format.
Additional columns were added as calculations: body mass index (weight in
kilograms/height in meters2), weight lost (starting weight minus ending weight), and
percent body weight lost (weight lost/starting body weight). Age was also calculated
using starting date minus birth year. These additional variables were also calculated per
session and put into the “per session” format.
Hypotheses and Statistical Analysis
Data collected were both quantitative and qualitative. The qualitative data were
categorized and into themes, then converted to quantitative. All data were then at the
interval-ratio or categorical level. Descriptive statistics were calculated to determine the
means and standard deviations for classes attended, food diaries submitted, weight lost in
pounds, and age for sessions one through five. Mean weight lost was also calculated for
classes one through 10 and then sessions one through five. SAS software package was
used for data analysis and significance was determined at the .05 level. For clarity, the
hypotheses are repeated below.
•

Hypothesis 1: UK employees who complete one session of WLM will cease
taking their blood pressure medications 6 months after WLM

•

Hypothesis 2: UK employees who complete one session of WLM will cease
taking their blood pressure medications 12 months after WLM.
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•

Hypothesis 3: UK employees who complete one session of WLM will cease
taking their diabetes medications 6 months after WLM.

•

Hypothesis 4: UK employees who complete one session of WLM will cease
taking their diabetes medications 12 months after WLM.

•

Hypothesis 5: UK employees who complete one session of WLM will cease
taking their cholesterol medications 6 months after WLM.

•

Hypothesis 6: UK employees who complete one session of WLM will cease
taking their cholesterol medications 12 months after WLM.

For research hypotheses one through six, the dependent variable was the change in
prescription data claims (specific to each condition). The independent variable was
completion of WLM (yes or no). Both variables were treated as dichotomous:
completed or not completed and on medications or off medications. A Chi Square test
was completed for hypotheses one, two, and six. A Fisher’s exact test was performed for
hypotheses three, four and five.
Because there were no significant values using data from participants who completed
one session, these same analyses were conducted again for those who completed two
sessions of WLM. The analyses were not conducted after three or more sessions because
the n became too small.
•

Hypothesis 7: The higher the attendance rate (attendance of WLM classes), the
more weight lost in UK employees at the end of the first WLM session.

For research hypothesis seven, the dependent variable was weight lost. The
independent variable was the attendance rate at WLM (0-10); a continuous variable. A
linear regression was conducted to compare those who registered for one session with
percent lost weight. After learning there was a positive association between classes
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attended and weight lost, linear regression was completed to determine if there was a
certain number of classes at which there was no significance or a certain number at which
the significance began.
Hypothesis 8: Percent of body weight lost (weight lost/starting body weight) for UK
employees who completed one session of WLM will increase at the end of the first WLM
session compared to starting weight when controlled for sex.
For research hypotheses eight, the dependent variable was body weight lost; a
continuous variable. The independent variable was classes attended; also a continuous
variable. A one way ANCOVA was conducted to compare percent weight loss of those
who completed one session and those who did not complete one session, with sex as the
co-variate.
•

Hypothesis 9: Percent of body weight lost (weight lost/starting body weight) for
UK employees who completed one session of WLM will increase with increased
food diary compliance.

In research hypothesis nine, the dependent variable was the percent body weight lost,
a continuous variable. The independent variable was food diary compliance. Linear
regression was performed to test the effect of food diaries on weight loss. Food diaries
were broken into three variables: compliance (6 or more), non-compliance (1-5), and
non-reporting (no data). The effects of compliance versus non-compliance was
compared to weight loss. Then the effects of reporting (either compliant or not) versus
non-reporting was compared to weight loss.
•

Hypothesis 10: A composite of variables: physical activity, sex, food diary
compliance, and weight loss goal will significantly predict a change in percent
body weight.
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In research hypothesis 10, the dependent variable is the change in percent body
weight. The independent variables were: presence of physical activity (yes or no), sex
(male or female), food diaries (completers, non-completers, and non-reporting), and goal
(1-7). Physical activity was included as a variable because it was part of the data set
collected from the intake form. One week out of ten per session was spent on the topic of
physical activity. A multiple regression analysis was completed to determine if the
independent variables predicted weight loss.
•

Hypothesis 11: A composite of variables including food diary compliance,
physical activity level, sex, age, weight loss goal, and percent body weight lost
will significantly predict a change in blood pressure prescription claims.

•

Hypothesis 12: A composite of variables including food diary compliance,
physical activity, sex, age, weight loss goal, and percent body weight lost will
significantly predict a change in cholesterol prescription claims.

•

Hypothesis 13: A composite of variables including food diary compliance,
physical activity level, sex, age, weight loss goal, and percent body weight lost
will significantly predict a change in diabetes prescription claims.

In research hypotheses 11-13, the dependent variable was the presence of medications
(specific to three conditions) at six months post and twelve months post, for each
condition separately. The predictor variables included: sex (male or female), age, percent
body weight lost, presence of physical activity (yes or no), food diary compliance (yes or
no), goal (1-7), and attendance as a categorical variable (completers or non-completers).
Logistic regression was performed for each drug category at six months post WLM and
12 months post WLM. The logistic regression was repeated treating attendance as a
continuous variable for each hypothesis. The analysis was repeated again for those who
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completed two sessions of WLM for hypertension only. The number of participants who
completed two sessions and were on cholesterol or diabetes medication was too small to
test.
Categorization
Most of the analyses were performed only for those who completed one session.
This was for several reasons. In hypotheses one through six, comparisons were drawn at
six months post and 12 months post WLM for each drug as compared to the start to see if
participants were able to get off of any of their medications after one session. Though it
seems logical that the longer a person stays in WLM, the more likely he/she is to come
off his/her medications, this may not always be true. Consider the person who completes
a 10 week session, waits six months, then completes a second 10 week session. This
scenario may not bring about drug changes in the same way as a person who completed
multiple 10 week sessions in a row. Secondly, those who complete more than one
session may no longer have a goal of weight loss, but weight maintenance. In this
scenario, the weight is not changing so the medications may not change either. Finally,
the total n decreases significantly after each 10 week session (Table 3.2). For these
reasons, which could not be controlled for, the data were analyzed in hypotheses one
through six after the first session. The first six analyses were also conducted after
completing two sessions of WLM, regardless if these sessions were back to back or
spread over time.
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Table 3.2
Number of participants who completed the corresponding number of sessions

1 Session
2 Sessions
3 Sessions
4 Sessions
5 Sessions
6 Sessions
7 Sessions
8 Sessions
9 Sessions
10 Sessions
11 Sessions
12 Sessions
13 Sessions
14 Sessions
15 Sessions
16 Sessions
17 Sessions

N
591
273
155
105
76
50
36
27
17
15
12
8
8
6
5
3
3

This chapter describes the methods used to determine if participants stopped
taking medications, if attendance was correlated with weight loss, if food diary
compliance was correlated with weight loss, and if any of the variables were predictive of
weight loss or medication cessation. Most analyses were conducted after one session of
WLM and repeated after two sessions of WLM.
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Chapter 4
Results
This chapter presents and briefly discusses the results of the study analyses.
Included in this chapter are descriptive statistics; Chi Square, Fisher’s Exact, logistic and
multiple regression for the testing of 13 hypotheses, and discussion of the findings.
Descriptive Statistics
There were 591 people in the study (66 men and 525 women) who attended at
least one session of WLM. On average, participants were 45 years old (SD 11.17),
attended approximately five and one half classes (SD 2.88), and completed a little less
than three-and one-half food diaries (SD 3.32) in ten weeks. Participants attended
anywhere from one class to ten classes in a session. Completers were defined as those
who attended six or more classes in a ten-week session (n = 309 for Session 1). The
average weight loss was almost five pounds in ten weeks (SD 5.86). The majority (n =
573) of Body Mass Indexes (BMI) were between 25.77 and 40.17. Only 18 participants
(3%) had a BMI of 24.17 or below, putting them into the “normal” category. The
categories for BMI are: Underweight = <18.5, Normal weight = 18.5-24.9, Overweight =
25-29.9, and Obese = 30 or >. Table 4.1 displays the descriptive statistics for those who
registered for one session through five sessions. Figure 4.1 shows BMI distribution for
the whole sample of 591.
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Table 4.1
Descriptive Statistics-Sessions 1 through 5
Session 1
(N = 591)

Session 2
(N = 273)

Session 3
(N = 155)

Session 4
(N = 105)

Session 5
(N = 76)

Variable Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Min

Max

Classes
Attended

5.60 (2.88)

5.04 (2.73)

4.86 (2.54)

5.6 (2.92)

4.85 (2.62)

0

10

Food
Diaries

3.43 (3.32)

2.27 (3.12)

2.21 (3.01)

2.9 (3.65)

2.23 (3.14)

0

10

Weight
Loss

-4.84 (5.86)

-2.03 (3.88)

-0.95 (3.45)

-2.40 (4.9)

-0.83 (4.7)

6.8

-33.1

Age

45.28
(11.17)

46.55
(10.98)

47.46
(11.03)

47.51
(10.83)

47.29
(1.30)

22

79

Figure 4.1
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Out of the 591 participants, 57.6% were not on medication at all (average age =
41.7 years). With an average age of 52.6 years, 16.4% were on cholesterol medication.
With an average age of 46 years, 2.3% were on diabetes medication. With an average age
of 48.8 years, 23.6% were on hypertension medications. Only eight were on a
combination of cholesterol and hypertension medications, one on a combination of
cholesterol and diabetes medications, and two on hypertension and diabetes medications.
Table 4.2 displays breakdown of the number of participants in each medication category
in relation to BMI categories.
Table 4.2
BMI category and medication category totals
Hypertension

Cholesterol

Diabetes

BMI < 24

2

1

0

BMI 24-30

22

13

1

BMI >30

43

34

9

It is clear from this table that the higher the BMI, the more medications a
participant was taking. More people were taking hypertension medications than both
cholesterol and diabetes combined.
Prescription use at six and 12 months post WLM
To answer the first six research hypotheses, two analyses were completed for
each: a Chi-Square as well as Fisher’s Exact. A Chi Square was chosen because the two
variables were categorical, i.e., either the participant completed WLM or they did not and
the participant either came off the medications or stayed on the medications. The
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equation for Chi Squared is X2 = Σ (observed value-expected value)2/expected value. For
n values below five, the Fisher’s exact test was applied. The equation for Fisher’s exact is
(a+b)!*(c+d)!*(a+c)!*(b+d)!/n!*a!*b!*c!*d! where a = non-completers who got off the
medications, b = non-completers who did not get off the medications, c = completers who
got off the medications, and d = completers who did not get off the medications. N = the
sample size for each time frame. Hypothesis 1: UK employees who complete one session
of WLM will stop taking their blood pressure medications 6 months after WLM.
Hypothesis 2: UK employees who complete one session of WLM will stop taking their
blood pressure medications 12 months after WLM. These were two-by-two tables
comparing presence of drug at six months and 12 months post-WLM for completers and
non-completers for each drug category: hypertension, cholesterol, and diabetes. Table
4.3 shows the number of completers who stopped taking medications at different
intervals with no substitutions. Tables 4.4, 4.5, and 4.6 are the two by two contingency
tables for each medication.
Table 4.3
Completers (after completing one session) on medications
Drug Free Post
Completers
N

Six Months
N

%

Twelve Months
N

%

Hypertension

81

17

20.9

23

23.4

Diabetes

10

3

30.0

3

30.0

Cholesterol

44

3

6.8

8

18.2

Note: Completion of program was defined as attendance at six or more classes.
This table shows, for example, that 81 participants completed one session of
WLM and were on hypertension medicine before the program began. Though the results
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were not statistically significant, at six months after completing the program,
approximately 21% of participants stopped taking their hypertension medications and at
12 months after completing the program, approximately 23% stopped taking their
hypertension medications. Similar results were calculated for diabetes and cholesterol
though the overall number of completers in these groups were lower.
Table 4.4
Completers compared to non-completers after one session for hypertension medications 6
and 12 months post
Session 1-6 months
Non completers
Completers
Total

Got off meds
14
17
31

Stayed on meds
71
64
135

Total
85
81
166

Session 1-12 months
Non completers
Completers
Total

Got off meds
16
23
39

Stayed on meds
69
58
127

Total
85
81
166

This table shows that 17 participants stopped taking their hypertension
medications six months after completing one session of WLM compared to 14 who did
not complete the program. At 12 months after, 23 participants stopped taking
hypertension medications after completing one session of WLM compared to 16 noncompleters.
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Table 4.5
Completers compared to non-completers after one session for diabetes medications 6 and
12 months post
Got off meds
Stayed on meds
Total
Session 1-6 months
Non completers
2
16
18
Completers
3
7
10
Total
5
23
28
Session 1-12 months
Non completers
Completers
Total

Got off meds
2
3
5

Stayed on meds
16
7
23

Total
18
10
28

Like the previous table, Table 4.5 shows three participants completed one session
of WLM and stopped taking diabetes medication six months after, compared to two who
did not complete one session. At 12 months, there were three participants who stopped
taking diabetes medication after completing one session compared to two participants
who did not complete the program. Table 4.6 shows similar results, only for cholesterol
medication and those who completed and stopped taking medication compared to those
who did not complete the program.
Table 4.6
Completers compared to non-completers after one session for cholesterol medications 6
and 12 months post
Session 1-6 months
Non completers
Completers
Total

Got off meds
7
3
10

Stayed on meds
40
41
81

Total
47
44
91

Session 1-12 months
Non completers
Completers
Total

Got off meds
10
8
18

Stayed on meds
37
36
73

Total
47
44
91
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There was no statistical significance between UK employees who completed one
session of WLM and ceased their blood pressure, diabetes, or cholesterol medications six
months or 12 months after WLM. This led to further investigation to see if two sessions
of WLM would be impactful.
Because there were no statistically significant associations between UK
employees who completed one session of WLM and cease taking their medications for
hypertension, cholesterol, or diabetes, the analyses were repeated to test whether there
was a significant association between UK employees who completed more sessions of
WLM and cease taking their medications. Therefore, Chi Square and Fisher’s Exact tests
were performed again after two sessions of WLM were completed. These results were
significant for hypertension drugs six months post-WLM and 12 months post-WLM for
completers. The number of observations past two completed sessions was too small to
conduct data analysis (see Table 4.7).
There was a statistically significant association between UK employees who
completed two sessions of WLM and ceased taking their blood pressure medications six
months after WLM χ2. (1) = 5.5547, p < 0.0184 compared to those who did not complete
two sessions. There was a statistically significant association between UK employees
who completed two sessions of WLM and cease taking their blood pressure medications
twelve months after WLM χ2. (1) = 11.0929, p < 0.0009 compared to those who did not
complete two sessions. For those who completed two sessions, 32% came off their
hypertension medications six months after WLM. For those who completed two
sessions, 50% came off their hypertension medications 12 months after WLM.
Statistically, participants were more likely to cease taking their medications after
completing two sessions of WLM than non-completers.
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Table 4.7
Completers (after completing two session) on medications
Drug Free Post
Completers
N
Hypertension
Diabetes
Cholesterol

Six Months
N

Twelve Months

%

N

%

28

9

32.1*

14

50.0**

4

0

0.0

1

25.0

14

1

7.1

3

21.4

Note: Completion of program was defined as attendance at six or more classes.
*p = <0.05, **p = <0.001
Table 4.7 shows the number of completers who were on medications and stopped
taking medication at six and 12 months after completing two sessions of WLM. For
example, there were 28 participants who completed two session of WLM and were on
hypertension medications prior to starting. After completing two sessions, 32% stopped
taking medication and after 12 months, 50% stopped taking hypertension medications.
Similar results are shown for diabetes and cholesterol medications for those who
completed two sessions.
Table 4.8
Completers compared to non-completers after two sessions for hypertension medications
6 and 12 months post
Session 2-6 months
Non completers
Completers
Total

Got off meds
5
9
14

Stayed on meds
43
19
62

Total
48
28
76

Session 2-12 months
Non completers
Completers
Total

Got off meds
7
14
21

Stayed on meds
41
14
55

Total
48
28
76
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Table 4.8 displays the two by two contingency tables for completers compared to
non-completers who stopped taking hypertension medications at six and 12 months post
WLM. For example, nine completers stopped taking medications six months after two
sessions of WLM compared to five non-completers. These results were statistically
significant.
Table 4.9
Completers compared to non-completers after two sessions for diabetes medications 6
and 12 months post
Session 2-6 months
Non completers
Completers
Total

Got off meds
4
0
4

Stayed on meds
5
4
9

Total
9
4
13

Session 2-12 months
Non completers
Completers
Total

Got off meds
3
1
4

Stayed on meds
6
3
9

Total
9
4
13

Table 4.9 displays the results of the two by two contingency tables for completers
compared to non-completers at six and 12 months after completing two sessions of WLM
who stopped taking diabetes medication. Table 4.10 displays similar results, only for
cholesterol medication
Table 4.10
Completers compared to non-completers after two sessions for cholesterol medications 6
and 12 months post
Session 2-6 months
Non completers
Completers
Total

Got off meds
3
3
6

Stayed on meds
23
11
34

Total
26
14
40

Session 2-12 months
Non completers
Completers

Got off meds
4
1

Stayed on meds
22
13

Total
26
14
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Table 4.10 (continued)
Total

5

35

40

There was not a statistically significant association between UK employees who
completed two sessions of WLM and cease taking their diabetes (n = 4) or cholesterol (n
= 14) medications six months or 12 months after WLM compared to those who did not
complete two sessions. Twelve months after two sessions, 25% of completers ceased
taking diabetes medications and 21.42% ceased taking cholesterol medications.
For those who completed one session of WLM, a sub-sample of low BMI (below
30) and high BMI (30 and above) was tested via Chi Square analysis. Because there
were only 18 participants in the normal category, a different stop point had to be
determined. Therefore, below 30 BMI were compared to above 30. There was no
significant difference between groups for those who ceased taking hypertension (n = 81),
cholesterol (n = 44), or diabetes (n = 14) medications 12 months after one session of
WLM (see Table 4.11). On average, the low BMI group lost 2.18% body weight and the
high BMI group lost 3.52% body weight in one session of WLM. This might be due to
the low BMI group having such a small n. There were even fewer participants on
medications after two sessions, which made analysis unwarranted.
Table 4.11
12 months after completing one session by BMI group

Low BMI

On
18

High BMI

40

Hypertension
Off
7
16

61

Cholesterol
On
Off
8
2

Diabetes
On
Off
1
0

28

9

6

4

Attendance and percent body weight lost
Hypothesis 7: The higher the attendance rate (attendance of WLM classes), the
more weight lost in UK employees at the end of one WLM session. For the seventh
hypothesis, a linear regression analysis was chosen to test if the predictor variable
(classes attended) accurately predicted the dependent variable (percent weight loss).
Using classes attended as a continuous variable, the results showed the variable of classes
attended was significant, F(1,587) =318.60, p = < 0.0001 for percent weight lost. The
more classes attended, the more weight lost in one session. This can be seen in the fit
plot in Figure 4.2 and the equation: Y = a + bX where Y is percent weight lost, a is
intercept, b is the slope of the line and X is classes attended.
Figure 4.2
Fit Plot of classes attended and percent weight loss
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There were 589 participants who enrolled in one session of WLM with records for
classes attended. The fit plot shows classes attended (β = 0.577) is positively associated
with percent weight lost R2 = 0.35, Pr > [t] of < 0.0001. As the number of classes
attended increased, the probability of weight loss increased.
The weight loss percent mean is 2.38; meaning people lost an average of
approximately 2.4% (SE = 0.032) body weight in one 10-week session. For a 200-pound
person, this would equal 4.8 pounds per 10-week session.
Linear regression was repeated investigating each level of classes attended (i.e., 210). Linear regression modeling indicates that attending four classes or more had a
statistically significant association with percent weight lost compared to those who only
attended one class F(9,589) = 39.92, p < 0.001. The mean percent weight lost per classes
attended within a 10-week session are shown in Table 4.12. For a 200-pound person, at
four weeks, they would have lost 1.4 pounds on average. This is not as meaningful,
though it is statistically significant. For a 200-pound person, at six weeks, they would
have lost 3 pounds on average. See table 4.12 for mean percent weight lost per number
of classes attended and Table 4.13 for estimates.
Table 4.12
Percent weight loss per class attended for one session (N=589)
Classes
attended

Mean (SD)
1 0.12 (1.05)
2 0.3 (1.52)
3 0.35 (1.63)
4 0.67 (1.84)
5 1.0 (2.27)
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Table 4.12 (continued)
6 1.48 (2.38)
7 1.48 (2.0)
8 2.36 (2.55)
9 2.79 (3.11)
10 4.69 (3.34)

Table 4.13
Multiple regression modeling the association of percent body weight lost with number of
classes attended as predictor variables (n=589)
Predictor Variable
Intercept

Estimate (SE)
20.88 (2.57)

2 classes attended

-0.46 (0.44)

3 classes attended

-0.39 (0.40)

4 classes attended

-1.24 (0.43)*

5 classes attended

-1.53 (0.43)**

6 classes attended

-2.06 (0.40)**

7 classes attended

-1.80 (0.43)**

8 classes attended

-3.67 (0.43)**

9 classes attended

-4.08 (0.42)**

10 classes attended

-5.42 (0.40)**

Note: * p = 0.0004, ** p = <0.001
Attendance and percent body weight lost-Sex
Hypothesis 8: Percent of body weight lost (weight lost/starting body weight) for
UK employees who completed one session of WLM will increase at the end of the first
WLM session compared to starting weight when controlled for sex. To test the eighth
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hypothesis, an analysis of co-variance was used on 586 records of those who enrolled in
one session of WLM who had sex recorded. An ANCOVA was chosen because the
predictor variable (attendance) was categorical. The dependent variable was percent
weight lost. Sex was the co-variant. The main effect of sex yielded an F ratio of
F(2,583) =1.05, p = 0.31, indicating that sex was not significant. The equation used was:
Y = b0 + b1X1 + b2X2 where Y is percent weight lost, X1 is female, X2 is classes attended
and b is the change in Y relative to the change in X. Table 4.14 displays the results of
this analysis.
Table 4.14
Analysis of Co-variance for sex on weight loss
Estimate (SE)

Pr > [t]

Intercept

-0.592 (0.339)

0.082

Female

-0.303 (0.295)

0.305

Male

0.000

Food diaries and percent body weight lost
Hypothesis 9: Percent of body weight lost (weight lost/starting body weight) for
UK employees who completed one session of WLM will increase with increased food
diary compliance. An analysis of covariance for the ninth hypothesis used 454 records as
this was the number who enrolled in one session and had data for food diaries. An
ANCOVA was chosen to determine if a statistically significant difference between food
diary compliance and the dependent variable (percent weight loss) were present for those
who completed one session compared to those who did not complete one session. The
covariate is attendance; whether participants completed six or more classes (compliant)
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or less than six classes (non-compliant). The model showed the effect of food diaries
completed was significant F(2,451) =116.85, p = <0.0001 for those who attended six or
more classes. The more food diaries completed the more percent body weight lost. This
can be seen in the fit plot in Figure 4.3 and the equation: Y = b0 + b1X1 + b2X2 + b3X3
where Y is percent weight lost, b0 is the slope of the line and X1 is food diary compliance,
X2 is attended, and X3 is not attended.
Figure 4.3
Fit plot of food diary compliance and percent weight loss for compliers and noncompliers

To test the hypothesis another way, two linear regressions were conducted. The
food diary compliance variable was divided into three variables: compliance (6 or more
food diaries), non-compliance (0-5 food diaries), and non-reporting (missing data). The
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non-reporting variable could be between 0 and 10 food diaries, just not reported. The
first linear regression included food diary compliant (six or more diaries completed)
compared to non-compliant (N = 586). The second linear regression included nonreporting participants compared to reporting (N = 586). The first model indicates
compliance was statistically significantly associated with weight loss F(2,585) = 179.43,
p = <0.001 compared to non-compliance. The second model shows reporting was
statistically significantly associated with weight loss F(2, 585) = 184.02, p = <0.001
compared to non-reporting. Together these results mean reporting any food diaries is
better than not-reporting and reporting six or more food diaries was associated with better
weight loss than reporting five or less. Table 4.15 displays both model’s estimates and p
values.
Table 4.15
Two regressions modeling food diaries and weight loss
Model 1

Estimate (SE)

Pr > [t]

Compliant compared to non-compliant

0.82 (0.37)

0.026

0.49 (0.20)

0.013

Model 2
Reporting compared to non-reporting

Percent body weight lost and sex, PA, food diaries, and goal
Hypothesis 10: A composite of variables: physical activity, sex, food diary
compliance, and weight loss goal will significantly predict a change in percent body
weight. A multiple regression was performed utilizing weight loss percent as the
dependent variable and sex, physical activity (dichotomous), food diary compliance
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(continuous), and goal (categorical) as the predictor variables in 152 observations using
the equation: Y = b0 + b1X1 + b2X2 + b3X3... where Y is the dependent variable (weight
loss percent), b is the slope, and X2, X3… represents each predictor variable. Table 4.16
displays the number of participants in each goal category. The analysis found that
physical activity (p = 0.01) and food diary compliance (p < 0.0001) were significant
predictors, but not sex or goal R2 = .27, F(4,147) = 13.41, p < 0.0001.
Table 4.16
Number participants in each goal category
Goal 0-Weight Loss

351

Goal 1- Maintain

1

Goal 2-Feel better/look better

21

Goal 3- Doctor’s suggestion/medical reason

1

Goal 4- 0+1

1

Goal 5- 0+2

40

Goal 6- 1+2

0

Goal 7 - 0+3

1

Multiple regression was repeated for one session enrollees another way. The
second linear regression compared those who attended (six or more classes) and dummy
variable, who were food diary compliant (six or more diaries) and dummy variable, food
diary reporting and dummy variable, physical activity reported and dummy variable, and
each of seven goals with corresponding dummy variables. The model was significant F
(10, 350) = <.001 and when physical activity was not reported, these cases were not
included. Attending six or more classes and having a goal of “doctor’s
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suggestion/medical condition” were both significant for percent weight lost in the second
model. Physical activity was not significant in this model, though it was in the first
model (p = 0.10). Table 4.17 shows which variables significantly predicted weight loss
percent for this second model.
Table 4.17
Multiple regression modeling the association of percent body weight lost with potential
predictor variables (N=350)

Intercept

Model 2
Estimate (SE)
4.55 (7.93)

Physical activity reported

-0.34 (0.20)

Attended six or more

0.88 (0.24)**

Food Diary compliant

0.43 (0.56)

Food diary Reporting

0.30 (0.21)

Goal 0 “Weight loss”

-1.79 (1.81)

Goal 1 “maintain”

N/A

Goal 2 “Feel better/look better”

-1.37 (1.86)

Goal 3 “Doctors suggestion/medical

9.80 (2.55) ***

Predictor Variable

reason”
Goal 4 = 0+1

-3.54 (2.56)

Goal 5 = 0+2

-1.69 (1.83)

Goal 6 = 1+2

-2.26 (2.55)

Goal 7 = 0+3

0

Note: * = p < .05, ** = p <.001, *** = p < .0001
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Table 4.17 indicates the estimate (SE) for each predictor variable on weight loss.
The goal of “doctor’s suggestion/medical reason” was statistically significant though
there was only one participant in this model with this goal.
Hypertension
Hypothesis 11: A composite of variables including food diary compliance,
physical activity level, sex, age, weight loss goal, and percent body weight lost will
significantly predict a change in blood pressure prescription claims.
The first logistic regression analysis of 88 observations was conducted with the
dependent variable being presence of hypertension medications six month post-WLM
(dichotomous). Sex, physical activity, classes attended (continuous), food diary
compliance (continuous), goal, age, and percent body weight lost were predictor
variables. The number of participants used in this analysis was 88 because this was the
number of participants who reported hypertension medication use data at twelve months
prior to WLM. Logistic regression was chosen because the dependent variable (presence
of medication six months post-WLM) was dichotomous and this analysis was chosen to
determine the relationship of the six variables to the dependent variable. The model was
not significant, indicating the variables did not have a statistically significant relationship
Pr > χ2 = 0.083. The equation for the model is p = exp(b0=b1X1+b2X2…)/1+ exp
(b0=b1X1+b2X2…) where the p is the expected probability that the outcome is present, the
X represents the predictor variables, and the b represents the coefficients.
The model was repeated with the dependent variable being presence of
hypertension medications 12 month post-WLM and sex, presence of physical activity,
classes attended (continuous), food diary compliance (continuous), goal, age, and percent
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body weight lost as predictor variables. The model was not significant, indicating the
variables did not have a statistically significant relationship Pr > χ2 = 0.23.
A second regression analyses of 88 observations was conducted using sex,
physical activity reported or not, goal one through seven and corresponding dummy
variables for each as predictor variables and getting off hypertension medications six
months after one session of WLM. This model was repeated using sex, physical activity
reported or not, goal one through seven and corresponding dummy variables for each as
predictor variables and getting off hypertension medications 12 months after one session
of WLM. Classes attended was a continuous variable for both models. Neither model
was statistically significant as shown in table 4.18.
Table 4.18
Logistic regression modeling each predictor variables effect on stopping hypertension
medication six and 12 months post WLM

Predictor variable

6 Months Post

12 Months Post

Estimate(SE)

Estimate(SE)

Intercept

7.09 (405.3)

1.11(1.75)

Sex-male

0.25 (0.43)

0.64 (0.42)

PA Start

0.47 (0.37)

-0.13 (0.28)

Classes _attended

-0.18 (0.19)

0.07 (0.16)

Food diary compliance

-0.15 (0.15)

-0.02 (0.11)

Goal 0

5.07 (63.24)

-0.43 (0.92)

Goal 1

0

0

Goal 2

0.26 (147.2)

-12.17 (379.6)

Goal 3

10.75 (382.9)

14.22 (690.6)
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Table 4.18 (continued)
Goal 4

0

0

0

0

Goal 6

0

0

Goal 7

0

0

Age

0.06 (0.03)

-0.05 (0.03)

Weight Loss Percent

0.29 (0.17)

-0.01 (0.13)

Goal 5

0

A final regression was conducted with the same variables as the previous analyses
for those who completed two sessions (n = 45) of WLM. The two sessions model had the
best fit (AIC = 37.34, SC = 39.15), though none of the variables were statistically
significant for ceasing medication likely due to the low n.
Cholesterol
Hypothesis 12: A composite of variables including food diary compliance,
physical activity, sex, age, weight loss goal, and percent body weight lost will
significantly predict a change in cholesterol prescription claims. A logistic regression
was completed using 48 records with the dependent variable being presence of
cholesterol medications six months post-WLM and sex, presence of physical activity,
classes attended (continuous), food diary compliance (continuous), goal, age, and percent
body weight lost as predictor variables. Forty-eight records were used as this was the
number of participants who were on cholesterol medications and had data recorded at
twelve months prior to WLM. The model was used again at 12 months post-WLM. The
models were not statistically significant Pr> χ2 = 0.44 and Pr> χ2 = 0.64, respectively.
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This is likely due to the low n. This model was considered again after two session of
WLM, however the n was too low to complete the analysis.
Diabetes
Hypothesis 13: A composite of variables including food diary compliance,
physical activity level, sex, age, weight loss goal, and percent body weight lost will
significantly predict a change in diabetes prescription claims. A logistic regression
analysis of 12 observations was conducted with the dependent variable being presence of
diabetes medications six month post-WLM and sex, presence of physical activity, classes
attended (continuous), food diary compliance (continuous), goal, age, and percent body
weight lost as predictor variables. Twelve observations were used as this was the number
of participants who were on diabetes medication and had values recorded twelve months
prior to WLM. The same model was used for a second analysis after 12 months. Neither
model was statistically significant, likely due to the low N Pr > χ2 = 0.15 and Pr > χ2 =
0.44. This model was also considered again after two sessions, but not able to be
completed due to the low n.
Discussion
There was a large difference between the number of men (66) and women (525)
included in the data set. Research has indicated women are greater users of healthcare
systems (Kramer, H.U., et al. 2012; Shalve, V., Chodick, G., and Kokia, E., 2005; Roy,
K. and Chaudhuri, A. 2008). This may account for the disproportionate number of males
verses females. Out of the total sample of 591 only 42.4% of participants were on any of
the three categories of medication at all. Only 10 participants had co-morbidities or were
on more than one category of medication. The average age of those on medications was
50.2 years and those not on medications was 41.7 years. This is in line with national
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trends. According to Gallup, 52% of Americans report taking prescription medication
while 48% report taking no prescription medications
(http://www.gallup.com/poll/20365/Half-Americans-Currently-Taking-PrescriptionMedication.aspx). For those 30-49, 40% report taking prescription medications while for
those 50-64, that number increases to 61%. In the 65 and over group, it rises to 88% on
medications.
For each of the 13 research questions, each question was asked after one session
of WLM and after finding no statistical significance the hypotheses were tested again
after two sessions of WLM. For some analyses, two sessions of WLM were found to be
adequate to find significant changes.
The first two research questions were similar, the only difference being whether
the analysis was conducted at six months or 12 months post-WLM. Hypothesis 1: UK
employees will cease taking blood pressure medications six months after completing one
session of WLM. There was no statistical significance six months after one session,
therefore the researcher asked the same question after two sessions and found a
statistically significant correlation between those UK employees who completed two
sessions of WLM and ceased taking their blood pressure medications six months postWLM and 12 months post-WLM. Though there was no statistically significant
association after one session, 21% of participants ceased taking their medications after
six months and 28% ceased taking them after 12 months. A study by Miller et al (2002)
demonstrated a large reduction of blood pressure lifestyle modifications, results similar to
medication therapy, for reducing blood pressure. Though their study was short (only 9
weeks), the significantly lower blood pressure was extrapolated to assume stopping
medications if continued long term. The results of the current study demonstrated
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subjects stopping blood pressure medications with weight loss after two sessions.
Hughes, Girolami, Cheadle, Harris, and Patrick (2007) found after 26 or 52 weeks in a
worksite wellness weight loss intervention, prescription claims decreased 44% in a
subgroup of 61, similar to the current study. Though the current study measured data for
five years, the number of participants who stayed in WLM for two sessions was 155 and
of those only 76 were taking blood pressure medications. While the other studies lacked
longitudinal data, the current study demonstrated participants ceased taking their blood
pressure medications six and 12 months after 20 weeks of a weight loss program. These
20 weeks may or may not have been continuous as previously described. One session
was 10 weeks and a participant may have waited any amount of time before starting
again or their enrollment may have been continuous without gaps. Regarding the
Transtheoretical Model, the participants who only stayed in one session (10 weeks),
might have been relapsing from action or they may have achieved their goal and moved
on to termination or maintenance. On the other hand, it is possible that those who stayed
in for two sessions or more might have relapsed and come back to action or stayed in
action throughout the whole 20 weeks.
In the same way, the third and fourth research questions were similar to one
another, conducting analysis at six months and 12 months post-WLM. Hypothesis: UK
employees will cease taking diabetes medications six months after completing one
session of WLM. Again, there was no statistical significance six months or 12 months
after WLM and the researcher tested again after two sessions of WLM. There was still
no statistically significant association. In a systematic review by Aucott (2008) and
another by Fujioka (2010), they highlighted several studies that showed a reduction in
blood glucose levels is highly associated with weight loss. None of these studies showed
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a complete removal of medications and suggested longer termed studies to see if there
were any effects on medication use. This current research has five years’ worth of data,
but the actual number of participants who stayed in WLM for more than two sessions (20
weeks) was 155 and of those, only 13 were on diabetes medication. In addition, the
current study only measured whether participants ceased taking their diabetes medicine,
not a reduction in medicine as previous studies had measured.
Research questions five and six were also similar. Hypothesis 5: UK employees
will cease taking cholesterol medications six months after completing one session of
WLM. Neither at six months or 12 months after one session of WLM, was there any
statistically significant association, therefore, the researcher tested the hypothesis again
six and 12 months after two sessions of WLM and still found no significance. After six
months, seven percent who completed two sessions ceased taking medication. After 12
months, 21% who completed two sessions ceased taking medication. The literature
supports HDL cholesterol improvement after maintaining weight loss for two years
(Matsuo, 2010). The current data set had only 40 participants using cholesterol
medications and staying in the program for two sessions (20 weeks).
Finkelstein, Linnan, Tate, and Leese (2009) looked at cost savings from all
medical claims (prescription and otherwise) in a sample of employees from 17 colleges
across North Carolina, but did not find significant effects for all claims. They did not
find significant cost savings for those who lost weight, except for pharmacy claims. This
current study partially supports those findings as hypertension medications were stopped
after two sessions. Though these numbers are small, these costs can add up over time.
Regarding diabetes and dyslipidemia, genetics might have influenced the results.
The average age of the participants was 45 years. There is potential that medications for
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these two conditions are not prescribed until later in life. In this sample, the average age
of those on medications was 50.2 years while the average age of those not on medication
was 41.7 which could be why there were no significant findings for diabetes or
cholesterol medication cessation. There were relatively few people on medications
(42.4% on medication). From a larger perspective, health promotion is often about
keeping the well well and working to move the higher risk participants along the scale
toward well. This is a demonstration of that idea.
The seventh analysis tested the hypothesis: The higher the attendance rate
(attendance of WLM classes), the more weight lost in UK employees at the end of the
first WLM session. The results showed the more classes attended, the more weight lost
with the weight loss percent mean of 2.4%. For example, for a 200-pound person, this
would equal 4.8 pounds lost in one session. From the descriptive statistics, the average
attendance for one session was 5.6 classes meaning participants, on average, lost about a
pound per week per class attended. Further investigation revealed attending four classes
was significantly associated with percent weight lost. This could have been due to the
participants’ readiness to change per the Transtheoretical model (TTM). After registering
and paying the fee, the participants were likely in the preparation stage, which is ‘ready
to take action in the next 30 days’, moving into action ‘overtly making changes in
behavior’. However, because stage of readiness was not measured, this assumption may
not be valid.
Johnson and colleagues (2008) and Logue et al. (2004) also found that staying in
the action stage or maintenance stage of the TTM had significant effects on long term
weight loss. Two sessions of WLM is 20 weeks, which could be action or maintenance,
but also might mean there is a relapse. Like the previously mentioned studies, this study
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also found that the longer a person attended, the more weight lost. Staying in WLM for
two or more sessions had significant effects on long term weight loss.
The eighth question was the same as number seven only controlling for sex.
There were no sex differences when comparing classes attended to percent body weight
lost. From the sample of 591, 11% were male, 89% female.
Hypothesis nine: Percent of body weight lost (weight lost/starting body weight)
for UK employees who completed one session of WLM will increase with increased food
diary compliance. There was a significant direct relationship in food diary compliance
and weight loss. Food diary compliance together with attendance completion have the
best case scenario for predicting percent weight loss. Food diary compliance is a form of
self-monitoring. In a systematic review of 22 studies regarding self-monitoring by
Burke, Wang, and Sevick (2011), 15 studies reported significant associations between
self-monitoring and weight loss. The current research supports this same finding.
The tenth research analysis utilized all the variables into a regression model and
was computed two ways. The hypothesis was: A composite of variables: physical activity
level, sex, food diary compliance, attendance, and weight loss goal will significantly
predict a change in percent body weight. Though the instrument to collect physical
activity information was not robust, the variable was included as part of the intake and
therefore included in the model, though it may affect the results. The results reinforced
the finding that attendance and food diaries have a statistically significant relationship on
weight loss. One goal had a statistically significant relationship to weight loss; having a
goal of doctor’s suggestion/medical reason increased the likelihood of losing weight.
Dixon and his colleagues (2009) conducted a study to uncover motivation to lose weight
with bariatric surgery. Their categories for motivation coincided with this research’s
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variable of goal. They found 69% choose “to improve a medical condition” or “to
improve health”. This is similar to this study’s option of “doctor’s suggestion/medical
reason”.
Hypotheses 11-13 were similar in that each tested for a change (off or on) in
prescription claims for each condition (hypertension, diabetes, and cholesterol) at six
months and 12-months post with all possible predictor variables using logistic regression
modeling. None of the results were statistically significant. However, since results from
hypotheses one and two showed two sessions were required for participants to cease
taking medications for hypertension, these hypotheses were tested again after two
sessions of WLM.
The 11th hypothesis was a composite of variables including food diary
compliance, physical activity level, sex, age, weight loss goal, and percent body weight
lost will significantly predict a change in blood pressure prescription claims six months
(and 12 months) post one session of WLM. There were no significant results after one
session. With two sessions, the N = 45, thus making analysis unsubstantiated as there
were 14 variables in the model.
The 12th hypothesis was a composite of variables including food diary
compliance, physical activity level, sex, age, weight loss goal, and percent body weight
lost will significantly predict a change in cholesterol prescription claims six months (and
12 months) post one session of WLM. There were no significant results after one
session. After two sessions, the N = 44 which was too small to analyze.
The 13th question was will food diary compliance, physical activity level, sex,
age, weight loss goal, and weight change predict a change in diabetes prescription
claims? The hypothesis was a composite of variables including food diary compliance,
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physical activity level, sex, age, weight loss goal, and percent body weight lost will
significantly predict a change in diabetes prescription claims six months (and 12 months)
post one session of WLM. There were no significant results after one session. After two
sessions, there were only 11 observations, which was too few on which to conduct
analysis.
The key idea of the socio-economic model that framed this study is that the three
levels (microsystem, mesosystem, and exosystem) all interact with each other.

The

variables at the microsystem level that were statistically significant were weight loss,
hypertension medication cessation, and food diary reporting. The significant amount of
percent body weight lost by participants found by this research could also be an effect of
the mesosystem level. At the mesosystem level, the weekly WLM group dynamics might
have affected the percent weight lost, food diary compliance, and attendance, though this
variable was not measured. Also, if participants signed up with a co-worker or friend,
this would be at the mesosystem level. Group dynamics or a “buddy system” was not a
measured variable, but could affect the results. Future programming could include
incentivizing signing up with an accountability partner or buddy. The reduction in
hypertension medications after two sessions of WLM affects the exosystem level in that
stopping medications means fewer pharmaceutical claims to the health plan. Because
UK has a self-funded health plan, cost savings to the health plan would get passed on to
the individual employee, affecting the microsystem again. The fact that higher
attendance and food diary reporting can affect weight loss demonstrates the interaction
between all three levels in that better attendance (microsystem) might be a result of who
is in the group or the supportive environment of the group (mesosystem). Increased
attendance (microsystem) could lead to increased weight loss for several or all of the
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group (mesosystem) and medication cessation which would affect the health plan costs
(exosystem).
Limitations
One limitation of this study was the lack of measurements, both biometric and
behavioral. The biometric measurement of blood pressure, blood glucose/AIC, or blood
cholesterol levels would provide a more precise determination of changes occurring in
the participant rather than relying on measuring medication cessation only. Behaviorally,
the lack of records for food diaries and physical activity reports were two measures that
were collected, but limited the study. Food diaries were not mandatory. Physical activity
was only self-reported at enrollment of each session and not throughout.
Another limitation was the advanced knowledge of pharmaceuticals needed to
determine if participants were reducing their medications instead of stopping their
medications. Reduction in medication could be via dosage, method of delivery, how
often it is taken, or the type of medication. The scope of this study was to determine if
participants ceased taking medications.
Finally, having low numbers of participants who were on medications for diabetes
and cholesterol limited the analysis. This is especially true regarding longitudinal
analysis or testing more than one 10-week session. Fewer and fewer participants
enrolled in subsequent sessions, lowering the total number available to test.
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Chapter 5
Summary, Conclusions, and Implications
This chapter will summarize the study, present conclusions, and discuss
implications for research and practice. Though culture is unique to each company or
organization, there are some ideas that apply to more general worksite wellness
programs.
Summary
The purpose of this study was to determine the effectiveness of the worksite
wellness weight loss program called Weight Loss Matters (WLM) for employees at the
University of Kentucky. The three main objectives were to measure the effect of Weight
Loss Matters on employees from June 2006 to December 2011 in the areas of (1)
prescription claims for hypertension, diabetes, and dyslipidemia, (2) weight loss, and (3)
food diary compliance.
Records were collected from paper files of WLM and from the UK Health Plan
claims database. These were merged into a single database for a final sample of 591
participants. Descriptive statistics were computed for those who completed one, two,
three, four, and five sessions. Most participants (all but 18) had a BMI in the overweight
or obese categories with most (n = 452) between 25.78 and 40.17. Chi Square,
ANCOVA and multiple and logistic regression were used to test the 13 hypotheses. The
results showed the more classes attended in a session, the greater the percent body weight
lost, regardless of sex. Also, results indicated that the more food diaries completed in a
session, the greater the percent body weight lost. Additional analysis indicated that after
two sessions of WLM, a significant number of participants were likely to cease taking
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their blood pressure medication, but no change was found for diabetes or cholesterol
medication users.
Conclusions
1. There were no statistically significant results for cessation of any medications
after one session of WLM in the whole sample.
2. After completing two sessions of WLM, there were statistically significant
changes in hypertension medication cessation at six and 12 months postWLM.
3. The participants demonstrated a statistically significant weight loss after one
session (10 weeks). Those who continued attendance (multiple sessions),
continued to have weight losses. For one session, attending four classes was
statistically significantly associated with weight loss.
4. There was a statistically significant positive association between food diary
compliance and weight loss. Both class attendance and completion of food
diaries were the strongest predictors of weight loss.
5. Having a goal of “doctor’s suggestion/medical reason” statistically
significantly predicted weight loss for those who enrolled in one session,
though only one person listed this as a goal.
Overall, the Weight Loss Matters program at the University of Kentucky has
achieved moderate gains for participants. Gains were seen in weight loss and stopping
hypertension medications after two sessions. Direct measurements of blood pressure,
blood glucose/A1C, and blood lipids might yield more positive results from the program.
In addition, modifications in the program (see implications section) could also yield more
effects.
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Implications
These results show value of the program on an individual level and a Universitywide level. Weight loss and medication cessation are important to people. As a result of
participation in a wellness program, people might feel better, look better, have better
health, have decreased medication costs, or decreased healthcare costs in general. This is
also of value on a greater scale. Happier and healthier employees have better morale, less
absenteeism, and less presenteeism. Fewer medication claims against the health plan
could cause the total cost of the health plan to the University to decrease. Since Weight
Loss Matters has achieved moderate gains for participants, it should be continued.
Attempts to improve the program should be undertaken and data should be collected to
determine if the changes are impactful.
After two sessions (20 weeks) of completing WLM, participants were
significantly more likely to cease taking their blood pressure medications. What is not
known is if the two sessions of WLM were back to back or had a time lapse. Since
changes were seen over time, the program facilitators might consider extending the
sessions from 10 weeks (current length) to 12-15 weeks. Since completion of one session
was considered six or more classes and people averaged 5.6 classes, two completed
sessions would mean approximately12 classes. While some have perfect attendance and
some only completed six classes, extending the program to 15 weeks would allow the
participants more time to address and implement the recommended behaviors and still
account for the average attendance of approximately half of the classes. Another option
would be to inform participants they are likely to achieve more weight loss and cease
taking their medications if they attend more classes. Knowledge alone can be a motivator
for behavior change, but as already demonstrated in the Transtheoretical Model, there are
84

several constructs that can affect actions toward behavior change. According to the WHO
(2003), there are five dimensions of adherence to both drugs and lifestyle modifications:
social/economic factors, therapy-related factors, patient-related factors, condition-related
factors, and health system/HCT-factors. Though WLM cannot affect all of these
dimensions, at least extending the program as an option can affect patient-related and
social/economic factors.

Additionally, incentives or challenges for attendance might

yield higher attendance and greater effects.
The WLM program should consider measuring blood pressure, blood
glucose/AIC, and blood cholesterol levels prior to the program and after the program to
more directly document possible reduction in these values that could lead to the stopping
of medications. Therefore, there is an opportunity for future research to examine other
data that could indicate success in the program
Because there was a significant relationship between food diaries completed and
percent body weight lost; the program should consider incenting the use of food diaries
instead of making it optional. For some participants, simply knowing that more food
diaries equal more weight lost might be incentive enough to complete them. For others,
added incentives for food diary completion could be a simple solution and added layer of
support for weight loss. The reason food diary completion was associated with increased
weight loss might be because the food diaries or that self-monitoring makes the behavior
more salient. Food diaries are not just about self-monitoring, but also for reflection and
insight about food choices. Another option for increasing food diary compliance is the
use of technology (i.e. a smart phone application), which is more readily available.
Physical activity was self-reported and not found to be a statistically significant
predictor of weight loss, consistently. Perhaps incorporating physical activity more
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fundamentally into the program and following up after one session would underline the
importance of physical activity to the participants. Once participants begin to lose weight,
exercise habits might change.
Because the goal of ‘doctor’s suggestion/medical condition’ was a significant
predictor of weight loss, the program could consider strengthening the referral process
between the WLM program and health care providers to gain more participants with this
goal. The current (to the time) system in places involved a full time Health and Wellness
staff person assigned to build relationships with the health care providers within the
University clinics with the hope of receiving more referrals from providers to Health and
Wellness professionals. However, only participant has this goal listed and therefore these
implications are speculative. The implications for increasing provider referrals could
lead to more weight loss for those who become enrolled, further reduction of
medications, and greater cost savings across the individual level and University wide.
No statistical significance was found for stopping diabetes or cholesterol
medications after one or two sessions of WLM. This was likely due to the low number of
participants who were taking these types of medications. Targeted marketing by WLM
staff to those with diabetes or dyslipidemia could result in greater numbers enrolled; then
more research could be completed. Other reasons for no significant changes for these
two conditions might also be the conditions themselves are related more to genetics when
compared to hypertension and less affected by food choices and activity habits
(behaviors). Considering the goal of “doctor’s suggestion/medical reason” was a
significant predictor of weight loss and there were no significant results for medication
cessations for cholesterol or diabetes, perhaps focusing on educating older persons to get
the appropriate checkups so the health care providers can then refer or suggest they lose
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weight because of a medical reason, this could have a positive effect on increasing
enrollment into the program.
There was a larger number of participants on hypertension medications with only
ten participants on multiple medications. In a study by Nguyen, Varela, Sabio, Naim,
Stamos, and Wilson (2006), for obese patients on multiple medications after bariatric
surgery the participants reduced the number of medications they were taking from 2.4 to
0.2. This research is informative in showing a reduction of medications, but does not
speak to which medications are stopped first. After searching current literature, there is
an apparent lack of research in finding which medications are stopped when
comorbidities are present.
Additionally, research to detect the time it takes for medications to be reduced or
stopped is also lacking. Though this current research demonstrated hypertension
medication cessation after 20 weeks for completers versus non-completers, there seems to
be mixed results in a research review. Aldana et al. (2005) demonstrated an improvement
in diabetes risk after six months of a Diabetes Prevention Program held within the
worksite. Fielding (1984) found hypertension improvements after one year. Finkelstein,
Linnan, Tate, and Leese (2009) found no medical cost savings at 12 months or the
subsequent two years after losing 5% body weight in a worksite wellness weight loss
program. However, Trogdon, Finkelstein, Reyes, and Dietz were able to demonstrate a
5% weight reduction resulted in a $90 per person savings in medical costs plus
absenteeism at one year. These varied results indicate a need for further research
regarding the time it takes to reduce or stop medication after weight loss.
This research has demonstrated positive effects for the employees at the
University of Kentucky. The research fits into the Strategic plan, as previously
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mentioned. It has potential to impact cost savings for the individual and also for the
University, also as previously mentioned. However, WLM could be used as a template
for other health promotion programs targeting weight loss and its effects in other
worksite wellness programs, but also in general. Community groups, health departments,
and civil organizations could use the WLM template to impact a greater number of
people. There are also possibilities for future research opportunities with the Health and
Wellness program working in close proximity with the faculty of the Kinesiology and
Health Promotion Department.
More broadly, this research has not only demonstrated its efficacy for health
promotion programming within worksite wellness programs, but could have greater
impacts on health promotion policy. The 1986 Ottawa Charter adopted by the WHO at
the first Global Conference on Health Promotion put health promotion on the global
radar. The charter has been updated, changed, and globalized even mores since then.
Specifically, in 2005, the 6th Annual Global Conference on Health Promotion which was
held in Bangkok, laid out four key action areas: “to make the promotion of health central
to the global development agenda, a core responsibility for all of government, a key focus
of communities and civil society, and a requirement for good corporate practices”
(http://www.who.int/healthpromotion/conferences/6gchp/bangkok_charter/en/). This
research fits into the fourth area of making health promotion a requirement for good
corporate practice. This includes promoting health and well-being to employees and their
families.
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Appendix A
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Appendix B
Session start wt.

lbs.

Session start wt.

Session wt. loss goal
Dat

Session wt. loss goal

Weigh

Goal

Total

Met goal

Session start wt.

yes

lbs.

Goal

Date

lbs.

Weight

Goal weight

Total

Met goal

yes

Date

Goal weight

yes

no

lbs.

Session wt. loss goal

Weigh

Total loss

Met goal

Session start wt.

Session wt. loss goal
Dat

lbs.

lbs.

Weight

Total loss

Met goal

yes

no

Name:_____________________ Meal Plan: __________ kcal at _______ activity level
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NAME: _______________________

Appendix C

DIRECTIONS: Write the date in the space provided (each
box represents one day). On the left of each box, record
what you eat each day. On the right of each box, check
the boxes as you eat foods from each food group. At the
end of the day, you should have checked the number of
boxes in each food group as indicated by your meal plan.
MY MEAL PLAN:
Starch ____ exchanges

Meat ____ exchanges

Fruit ____ exchanges

Milk ____ exchanges

Vegetable ____ exchanges

Fat ____ exchanges

Breakfast

Lunch

Date _________

Starch
Fruit
Veggie

Dinner

Meat
Milk
Fat
Water

Breakfast

Lunch

Date _________

Starch
Fruit
Veggie
Meat

Dinner

Milk
Fat
Water
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Appendix D
Drug

Vytorin
Simvastatin

Simvastatin
Zocor

Crestor

alt name

ezetimibe/si
mvastatin
see above

Zocor
see above

rosuvastatin
calcium

uses

cholesterol
cholesterol

cholesterol
cholesterol

cholesterol

explanation

blocks the
absorption of
cholesterol from
food AND reduces
cholesterol the body
makes naturally

side effects
loss of appetite, upper belly pain,
dark urine, yellowing of skin or
whites of eyes, feel tired/weak;
headache, increased liver enzyme
levels, muscle pain, upper
respiratory infection, diarrhea;
allergic reactions, joint pain,
inflammation of pancreas, nausea,
dizziness, tingling sensation,
depression, gallstones, trouble
sleeping, poor memory,
confusion, ED, breathing
problems/cough/SOB

HMG-CoA
reductase inhibitor
(statin)

Headache, nausea, vomiting,
diarrhea, abdominal pain, muscle
pain, abnormal liver tests; liver
damage, muscle inflammation or
breakdown; rhabdomyolysis.

http://www.medicinenet.com/simvastatin/page2.htm

blocks enzyme in
liver causing liver to
make less chol and
increases uptake and
breakdown by liver
of chol already in
blood

muscle problems, liver problems,
headache, muscle aches,
abdominal pain, weakness,
nausea, high blood sugar,
memory loss/confusion

http://www.crestor.com/c/about-crestor/crestor-sideeffects.aspx
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Source

http://www.vytorin.com/ezetimibe_simvastatin/vyto
rin/consumer/about_vytorin/index.jsp?WT.mc_id=Y
03R1&utm_source=google&utm_medium=cpc&ut
m_term=vytorin&utm_campaign=Branded_2013&u
tm_content=swVnTtv9v|dc_pcrid_18912150850

Zetia

Pravastatin
Sodium

Atorvastatin
Calcium
Lipitor

ezetimibe

Prevachol

Lipitor
see above

cholesterol

cholesterol

cholesterol
cholesterol

works in digestive
tract to block
absorption of chol
from food you eat
reversible inhibitor
of the enzyme that
catalyzes the
conversion of
HMG-CoA to
mevalonate, early
and rate limiting
step in biosynthetic
pathway for chol.
Reduces VLDL and
TG and increases
HDL-C.
Inhibitor of HMGCoA reductase.
This enzyme
catalyzes the
conversion of
HMG-CoA to
mevalonate, an early
and rate limiting
step in cholesterol
biosynthesis

diarrhea, joint pain, feeling tired;
muscle problems, allergic
reactions, rash, joint pain, muscle
pain, alterations in lab tests, liver
problems, stomach pain,
inflammation of pancreas, nausea,
dizziness, tingling, depression,
headache, gallstones,
inflammation of gallbladder

http://www.zetia.com/ezetimibe/zetia/consumer/abo
ut-zetia/faqs.jsp

cardio angina pectoris, rash,
nausea/vomiting, diarrhea,
flatulence; dyspepsia/heartburn,
abdominal distension; fatigue,
chest pain, influenza, muscle
pain, myalgia, headache,
dizziness, pharyngitis, upper
respiratory infection, rhinitis,
cough

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780 and
http://www.drugs.com/pravastatin.html

nasopharyngitis, arthralgia,
diarrhea, pain in extremity, UTI,
dyspepsia, nausea,
musculoskeletal pain, muscle
spasms, myalgia, insomnia,
pharynogolaryngeal pain

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=d385e07a-c16f-4aef-8e55-af95bd1c7526
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Fenofibrate
Trilipix

TriCor
Fenofibrate
Micronized

Antara,
Fenoglide,
Lipidil,
Lipofen,
TriCor,
Triglide,
Trilipix
Fibricor

cholesterol
cholesterol

Fenoglide,
Tricor,
Lipofen,
Antara,
Triglide,
Lofibra

cholesterol

antillipemic agents,
speeds up natural
processes that
remove chol from
body

constipation, diarrhea, heartburn,
pain in back/arm/legs, headache

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a601052.html

cholesterol

Gemfibrozil

Lopid

cholesterol

GlyBURIDEMetformin

Glucovance

Diabetes

Janumet

sitagliptin
and
metformin
HCI

Diabetes

class: fibrates,
reduces the
production of
triglycerides in the
liver

glyburide/metformin
hydrocholoride
helps pancreas make
more insulin, helps
body more
effectively use the
insulin, and
decreases excess
sugar that your liver
makes

stomach pain, heartburn, muscle
pain/tenderness/weakness, blurred
vision
Lactic acidosis (can be fatal),
muscle pain/weakness, numb or
cold feeling in arms/legs, trouble
breathing, stomach pain, nausea
w/ vomiting, slow/uneven HR,
dizziness, feeling weak/tired.
Lactic acidosis (can be
fatal),pancreatitis (also fatal),
kidney problems, stuffy/runny
nose, sore throat, upper
respiratory infection, diarrhea,
nausea, vomiting, gas, upset
stomach, indigestion, weakness,
headache, low blood sugar
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https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a686002.html

http://www.rxlist.com/glucovance-drug.htm

http://www.janumetxr.com/sitagliptin_metformin_H
CL/janumetxr/consumer/what-isjanumet/index.xhtml

Metformin
Hydrochloride

Acarbose

Actos

actoplus
met,
Actoplus
Met XR,
Avandamet,
Fortamet,
Glucophage,
Glucophage
XR,
Glucovance,
Glumetza,
Janumet,
Metaglip,
Prandimet,
Riomet

Prandase or
Precose

pioglitazone

Diabetes

Diabetes

Diabetes

antihyperglycemic
agent, lowers basal
and postprandial
plasma glucose.
Decreases hepatic
glucose production,
decreases intestinal
absorption of
glucose, and
improves insulin
sensitivity by
increasing
peripheral glucose
uptake and
utilization.

Works by slowing
the action of certain
chemicals that break
down food to release
glucose into your
blood.
Thiazolidinedione
that depends on
presence of insulin
for action.
Decreases insulin
resistance in
periphery and liver,
resulting in
increased insulin
dependent glucose
disposal and
decreased hepatic
glucose output.

lactic acidosis, diarrhea,
nausea/vomiting, flatulence,
asthenia, indigestion, abdominal
discomfort, headache
shakiness,
dizziness/lightheadedness,
sweating, nervousness/irritability,
sudden changes in behavior or
mood, headache, numbness or
tingling around mouth, weakness,
pale skin, hunger, clumsy or jerky
movements

low blood sugar, liver problems,
bladder cancer, broken bones,
macular edema, ovulation, coldlike symptoms, headache, sinus
infection, muscle pain, sore throat
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http://www.fda.gov/ohrms/dockets/dailys/02/May02
/053102/800471e6.pdf and
http://www.drugs.com/monograph/metforminhydrochloride.html

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a696015.html

http://www.fda.gov/downloads/Drugs/DrugSafety/U
CM183833.pdf and
http://www.drugs.com/pro/actos.html

Avandia

Byetta

Glimepiride

GlipiZIDE
GlipiZIDE
Extended
Release
GlipiZIDE XL

rosiglitazone
maleate

Exenatide

Amaryl

Glucotrol

Diabetes

Increasing insulin
sensitivity, improves
glycemic control
while reducing
circulating insulin
levels. Improves
sensitivity to insulin
in muscle an adipose
tissue and inhibits
hepatic
gluconeogenesis.

Diabetes

Helps pancreas
make more insulin
more efficiently.

Diabetes

causes pancreas to
produce insulin
helps body use
insulin efficiently

Diabetes

causes pancreas to
produce insulin
helps body use
insulin efficiently

heart failure, swelling, low blood
sugar, fractures, weight gain,
anemia, ovulation, liver problems
low blood sugar, kidney
problems, severe allergic
reactions, nausea, vomiting,
diarrhea, feeling jittery, dizziness,
headache, acid stomach,
constipation, weakness
dizziness, nausea, yellowing of
skin or eyes, light colored stools,
dark urine, pain in upper right
stomach, unusual
bleeding/bruising, diarrhea, fever,
sore throat
diarrhea, gas, feeling jittery,
dizziness, uncontrollable shaking
of a part of the body, red or itchy
skin, rash, hives, blisters,
yellowing of skin or eyes, light
colored stools, dark urine, pain in
upper right stomach, unusual
bleeding/bruising, diarrhea, fever,
sore throat

Diabetes
Diabetes
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http://www.fda.gov/downloads/Drugs/DrugSafety/P
ostmarketDrugSafetyInformationforPatientsandProv
iders/UCM143413.pdf

http://www.fda.gov/downloads/Drugs/DrugSafety/U
CM191084.pdf and
http://www.drugs.com/byetta.html

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a696016.html

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684060.html

GlyBURIDE
GlyBURIDEMetformin

Humalog
Humalog
Cartridge
Humalog Pen

Lantus
Lantus
OptiClik
Cartridge
Lantus
Solostar Pen

Novolin R

Micronase,
DiaBeta,
Glynase,
glibenclami
de

Diabetes

causes pancreas to
produce insulin
helps body use
insulin efficiently

nausea, upper abdominal fullness,
heartburn, rash, yellowing of skin
or eyes, light colored stools, dark
urine, pain in upper right
stomach, unusual
bleeding/bruising, diarrhea, fever,
sore throat

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684058.html

regulation of
glucose, Is a form of
insulin

hypoglycemia, renal impairment,
hepatic impairment, allergy

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=b34cd3ff-d0af-4852-b4ef-2a8b4a93aeae#s20

long acting human
insulin analogues to
improve glycemic
control

headache, flu like symptoms,
dyspepsia, diarrhea, back pain,
pharyngitis, lipodystrophy,
lipohypertrophy, pallor,
palpitation, tachycardia, local
allergic reaction, hypokalemia,
peripheral edema

http://reference.medscape.com/drug/lantus-toujeoinsulin-glargine-999003#4

insulin-controls the
storage and
metabolism of
carbohydrates,
proteins, and fats

skin rash, SOB, fast HR,
sweating, drop in BP

http://dailymed.nlm.nih.gov/dailymed/archives/fdaD
rugInfo.cfm?archiveid=10574

Diabetes

insulin
lispro

Diabetes
Diabetes
Diabetes

insulin
glargine

Diabetes

see above

Diabetes

see above

Diabetes

Diabetes
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NovoLog
NovoLog
FlexPen

see above

NovoLog Mix
70/30 FlexPen

Prandin

Hydrochloroth
iazideLisinopril

insulin

hypoglycemia, headache, injury
accidental, nausea, diarrhea

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=3a1e73a2-3009-40d0-876c-b4cb2be56fc5

Diabetes

rapid acting and
long acting insulin
mix

hypoglycemia, headache, flue like
symptoms, dyspepsia, back pain,
diarrhea, pharyngitis, rhinitis,
skeletal pain, upper respiratory
tract infection

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=973a9333-fec7-46dd-8eb5-25738f06ee54

Diabetes

lowers blood
glucose by
stimulating the
release of insulin
from pancreas

HTN

Lisinopril is ace
inhibitor, relaxes
blood vessels.
Hydrochlorothiazide
is diuretic,

Diabetes

repaglinide

Prinzide or
Zestoretic

Diabetes

hypoglycemia, respiratory
infection, nausea, diarrhea,
constipation, vomiting, dyspepsia,
back pain, arthralgia, headache,
paresthesia, chest pain, UTI, tooth
disorder, allergy
blurred vision, body aches or
pain, chills, confusion, cough,
diarrhea, difficulty breathing,
dizziness, faintness,
lightheadedness, ear congestion,
fever, headache, loss of voice,
nasal congestion, nausea, runny
nose, sneezing, sore throat,
sweating, unusual tiredness or
weakness, vomiting; acid/sour
stomach, belching,
burning/crawling/tingling,
decreased libido, heartburn,
inability to have or keep erection,
indigestion, lack/loss of strength,
loss of sexual performance,
muscle cramps, rash, stomach
discomfort/pain;
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http://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2009/020741s035lbl.pdf

http://www.mayoclinic.org/drugssupplements/lisinopril-and-hydrochlorothiazideoral-route/description/drg-20069073

Hydrochloroth
iazideLosartan
Hydrochloroth
iazideTriamterene
Hydrochloroth
iazideValsartan
Avalide/Avapr
o
Irbesartan
Hydrochloroth
iazide

Metoprolol
Succinate ER
Toprol XL

Clonidine
Hydrochloride

HTN

Maxide-25

HTN

HTN
irbesartan,
hydrochlorot
hiazide

Toprol
see above

Clorpres

HTN
HTN

see above
see above

HTN

see above

HTN
HTN

HTN

http://www.fda.gov/Drugs/ResourcesForYou/Specia
lFeatures/ucm298226.htm

see above

Beta blocker
see above

drowsiness, dizziness, tiredness,
diarrhea, slow HR, decreased
sexual ability, cold feelings in
hands/feet; mood changes, SOB,
sudden wt gain; rash,
see above

antihypertensive
agent and diuretic

dry mouth, increased thirst,
drowsiness, feeling restless,
nausea, vomiting, increased
urination, muscle pain/weakness,
fast HR, lightheaded, fainting,
seizure, easy bruising/bleeding,
red or purple spots on skin,
confusion, hallucinations,
urinating more or less than usual,
SOB, swelling, rapid wt gain,
numbness/tingly, nausea, stomach
pain, low fever, loss of appetite,
dark urine, clay colored stools,
jaundice; dry mouth, loss of
appetite, diarrhea, constipation,
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http://www.webmd.com/drugs/drug-8814Metoprolol+Succinate+Oral.aspx?drugid=8814

http://www.rxlist.com/clorpres-drug/patient-imagesside-effects.htm

upset stomach, dizziness,
drowsiness, headache, feeling
restless or nervous, sleep
problems, nightmares or unusual
dreams, breast swelling or
tenderness, mild itching or skin
rash, impotence or loss of interest
in sex

Catapres-TTS1

clonidine,
transdermal
patch

HTN

Lisinopril

Prinivil or
Zestril

HTN

stimulates alphaadrenoceptors in
brain stem, resulting
in reduced outflow
from central nervous
system and decrease
in peripheral
resistance, renal
vascular resistance,
HR, and BP

dry mouth, drowsiness, fatigue,
headache, lethargy and sedation,
insomnia, dizziness,
impotence/sexual dysfunction,
dry throat, constipation, nausea,
change in taste, and nervousness
cough, dizziness, headache,
excessive tiredness, nausea,
diarrhea, weakness, sneezing,
runny nose, decrease in sexual
ability; swelling of
face/throat/tongue/lips/eyes/hands
/feet, hoarseness, difficulty
breathing/swallowing, fever, sore
throat, chills, signs of infection,
yellowing of skin or eyes,
lightheadedness, fainting, chest
pain
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http://dailymed.nlm.nih.gov/dailymed/archives/fdaD
rugInfo.cfm?archiveid=13567

Diovan HCT

valsartan
and
hydrocholrot
hiazide usp

Benicar

Olmesartan,
hydrochlorot
hiazide,
Atacand,
Avapro,
Cozaar,
Diovan,
Micardis,
Teveten

Nadolol

Metoprolol
Tartrate

Corgard

Lopressor

HTN

valsartan is
angiotensin II
receptor blocker and
hydrochlorothiazide
is diuretic

HTN

angiotensin II
receptor blocker,

HTN

beta-adrenergic
receptor blocker

HTN

beta-selective
(cardioselective)
adrenergic receptor
blocker.

Allergic reaction, breakdown of
skeletal muscle resulting in
kidney failure, eye pain/vision
problems, light headed or
fainting, swelling rapid weight
gain, fast or pounding HR,
urinating less than usual,
jaundice, dry mouth/increased
thirst, drowsiness, restless feeling,
confusion

http://www.rxlist.com/diovan-hct-drug/patientimages-side-effects.htm

see above

http://www.fda.gov/Drugs/DrugSafety/PostmarketD
rugSafetyInformationforPatientsandProviders/ucm2
15245.htm

Dizziness or lightheadedness,
excessive tiredness, SOB,
swelling in hands, feet, ankles,
lower legs; unusual wt gain,
fainting,
tiredness/dizziness, sob,
bradycardia, cold extremities,
arterial insufficiency, palpitations,
CHF, peripheral edema,
hypotension, wheezing, diarrhea,
nausea, dry mouth , gastric pain,
constipation. Flatulence,
heartburn, vomiting, pruritus/rash,
peyronies disease, pain. blurred
vision, tinnitus
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https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682666.html and
http://labeling.pfizer.com/ShowLabeling.aspx?id=70
8

http://www.drugs.com/cdi/metoprolol-tartrate.html
and
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=011ee828-5c2a-49b9-bf8e-07f5eb5fc635

Spironolactone

Amlodipine
Besylate

Afeditab CR

Aldactone

Norvasc,
Azor
nifedipine,
Adalat CC,
Afeditab
CR,
Nifediac
CC,
Nifedical
XL,
Procardia,

HTN

potassium-sparking
diuretic that
prevents the body
from absorbing too
much salt and keeps
potassium levels
from getting too low
besylate salt of
amlodipine, a long
acting calcium
channel blocker,
inhibits
transmembrane
influx of calcium
ions into vascular
smooth muscle and
cardiac muscle.
Amlodipine is
peripheral arterial
vasodilator causing
reduction in
peripheral vascular
resistance and
reduction in bp.

HTN

Calcium channel
blocker, relaxes
cardiac muscle and
blood vessels

HTN

vomiting, diarrhea, stomach
pain/cramps, dry mouth, thirst,
dizziness, unsteadiness, headache,
enlarge/painful breasts, irregular
menstrual periods, vaginal
bleeding in post men, difficulty
maintaining or achieving erection,
deepening of voice, increased hair
growth on body parts, drowsiness,
tiredness, restlessness

edema, dizziness, flushing,
palpitation
worsening angina, light headed,
pounding heartbeat, chest pain,
swelling in ankles or feet,
stomach pain, dizziness,
weakness, headache, mood
changes, heartburn, nausea,
tremors, muscle cramps, cough,
wheezing, sore throat or stuffy
nose
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https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682627.html and
http://www.drugs.com/spironolactone.html

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=2bac4ec4-9542-4927-8121-a7cd1858075b and
http://www.webmd.com/drugs/2/drug5891/amlodipine-oral/details

http://www.drugs.com/mtm/afeditab-cr.html

Procardia
XL

Nifediac CC
Nifedical XL
Nifedipine ER
Nisoldipine
Sular

see above
see above
see above
see above
nisoldipine

HTN
HTN
HTN
HTN
HTN

Amlodipine
BesylateBenazepril
Hydrochloride

Lotrel

HTN

Lotensin

benazepril
hydrochlorid
e

HTN

Atenolol

Tenormin

HTN

Bisoprolol
Fumarate

HTN

calcium channel
blocker and ACE
inhibitor, relaxes
blood vessels to help
flow
non-sulfhydryl
angiotensinconverting enzyme
inhibitor

Beta blocker,
Beta blocker-relaxes
blood vessels and
slows heart rate to
improve and
decrease BP.

dizziness, cough, swelling
hands/ankles/feet, fainting,
irregular heartbeat, high
potassium, weakness, sore throat,
liver problems, chest pain or heart
attack,

headache, dizziness, somnolence,
postural dizziness
dizziness, lightheadedness,
tiredness, drowsiness, depression,
nausea, diarrhea, SOB, swelling
of hands or feet, weight gain,
fainting
excessive tiredness, vomiting,
diarrhea, muscle aches, runny
nose; SOB, swelling of hand/feet,
unusual weight gain, fainting,
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http://www.fda.gov/Safety/MedWatch/SafetyInform
ation/ucm262165.htm and
http://www.webmd.com/drugs/2/drug11524/amlodipine-benazepril-oral/details#sideeffects

http://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2012/019851s042lbl.pdf

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684031.html

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a693024.html

Bystolic

Cartia XT

Diltiazem
Hydrochloride

nebivolol

diltiazem,
Cardizem

headache, fatigue, dizziness,
diarrhea, nausea, insomnia, chest
pain, bradycardia, SOB, rash,
peripheral edema

http://www.bystolic.com/

HTN

calcium channel
blocker, relaxes
blood vessels so
blood flows more
easily, lowers HR

dizziness, lightheadedness,
weakness, nausea, flushing,
constipation, headache

https://healthy.kaiserpermanente.org/health/care/con
sumer/health-wellness/drugs-and-naturalmedicines/drug-encyclopedia/medicineinformation/!ut/p/a1/hc_BTsJAEAbgpFIZ9qFdvG2gOK2ArU2UvdiSllbkmW3KQsNPr0U
8WCMOreZfPMnPwjIQOj8uC1zuzU6V90u_NcUXI8dhmiy4fI45AuppR6OCGwghBEqcz6gl8qaubHvZw0xxKqYtTvzaNVdL2EIQyRa4kZFL3D_t_
dXfjU8i8URBQ_MYLo63UtpF6IxvZ_MxejUG02fu
mYt0f02tCSxCNfOu4U5m9haxtW6c0plTSKczuXE
T83RWv4C58gTLwYgin0_uJ3wRIc6CK4gZcjrHoYuMMj9lETBfOHibHAFSPjjJWEW3i2URo9jyKC6H2BX4Yh1Dt6Iur4IJO1n9wm7AM
6_jt-/dl5/d5/L2dBISEvZ0FBIS9nQSEh/

HTN

calcium ion cellular
influx inhibitor
(slow channel

lower limb edema, sinus
congestion, rash NOS

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=813eb1bb-1475-4958-821d-e97c5abb7462

HTN

beta blocker, relaxes
blood vessels
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blocker or calcium
antagonist)

Carvedilol

Chlorthalidone

Cozaar

Coreg

Hygroton,
Thalitone

losartan
potassium

HTN

beta blocker, relaxes
blood vessels

HTN

water pill-causes the
kidneys to get rid of
unneeded water and
salt

HTN

Blocks the
vasoconstrictor and
aldosteronesecreting effects of
angiotensin II by
selectively blocking
the binding of
angiotensin II to the
AT receptor found
in many tissues.

extreme thirst, frequent urination,
extreme hunger, weakness,
blurred vision; tiredness,
weakness, lightheadedness,
dizziness, headache, diarrhea,
nausea, vomiting, vision changes,
joint pain, difficulty falling or
staying asleep, cough, dry eyes,
numbness, burning, or tingling in
the arms or legs
muscle weakness, dizziness,
cramps, thirst, stomach pain,
upset stomach, vomiting,
diarrhea, loss of appetite,
headache, hair loss
abdominal or stomach pain,
anxiety, bladder pain, bloody or
cloudy urine, blurred vision,
chills, cold sweats, coma,
consution, cool pale skin,
depression, difficult breathing,
difficulty burning or painful
urination, dizziness, fast
heartbeat, frequent urge to
urinate, headache, increased
hunger, irregular heartbeat, lower
back pain, nausea/vomiting,
nightmares, numbness or tingling
in hands feet or lips, pale skin,
seizures, shakiness, SOB, slurred
speech, trouble breathing w/
exertion, unusual bleeding or
bruising, unusual
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https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a697042.html

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682342.html

and
https://www.merck.com/product/usa/pi_circulars/c/c
ozaar/cozaar_pi.pdf

tiredness/weakness,
weakness/heaviness of legs

Doxazosin
Mesylate

HTN

Enalapril
Maleate

Felodipine

HTN
Plendil,
Lexxel (a
combination
drug)

HTN

Selective inhibitor
of alpha 1 subtype
of adrenergic
receptors. Results
in systemic vascular
resistance.
Maleate salt of
enalapril, the ethyl
ester of a long
acting angiotensin
converting enzyme
inhibitor,
enalaprilat.
Enalapril, after
hydrolysis to
enalaprilat, inhibits
angiotensinconverting enzyme
(ACE) .
calcium channel
blocker, relaxes
blood vessels so
blood flows more
easily, lowers HR

dizziness, fatigue, swelling of
feet, SOB

fatigue, orthostatic effects,
asthenia, diarrhea, nausea,
headache, dizziness, cough, rash
headache, flushing, dizziness or
lightheadedness, weakness, fast
heartbeat, heartburn, constipation,
enlargement of gum tissue around
teeth
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http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugX
sl.cfm?setid=345478a6-8389-4229-92b36e40da7b06fd

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=e31289f1-4b59-418a-a893-c748ce073f6c

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a692016.html

Fosinopril
Sodium

Monopril

Guanfacine
Hydrochloride

Intuniv,
Tenex

Hyzaar

Losartan
potassium
and
hydrochlorot
hiazide

Indapamide

Lozol

Labetalol
Hydrochloride

Minoxidil

Loniten,
Rogaine,
Renewal

HTN

hydrolyzed by
esterase to the
pharmacologically
active from,
fosinoprilat, a
specific competitive
inhibitor of
angiotensin
converting enzyme
(ACE)
alpha2Aadreneergic receipt
agonists-decreases
HR and relaxes
blood vessels to
blood can flow more
easily

HTN

angiotensin II
receptor antagonist
and a diuretic

HTN

water pill-causes the
kidneys to get rid of
unneeded water and
salt

HTN

adrenergic receptor
blocking agent

HTN

vasodilator-relaxes
blood vessels so
blood can flow more
easily

HTN

cough, dizziness, nausea,
vomiting, headache, diarrhea,
fatigue, sexual dysfunction

http://dailymed.nlm.nih.gov/dailymed/archives/fdaD
rugInfo.cfm?archiveid=4617

dry mouth, tiredness, weakness,
headache, irritability, decreased
sexual ability, decreased appetite,
stomach pain, nausea, vomiting,
constipation, fainting, blurred
vision, rash, slow HR

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a601059.html

abdominal pain, edema/swelling,
palpitation, dizziness, cough,
sinusitis, URI, rash
muscle cramps, drowsiness,
confusion, thirst, upset stomach,
vomiting, stomach cramps,
decreased sexual ability, blurred
vision

postural hypotension, increased
sweating, flushing
increase in size or darkness of
fine body hair, breast tenderness,
headache, nausea, vomiting; rash,
fast HR, swollen ankles/feet,
unexplained weight gain,
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https://www.merck.com/product/usa/pi_circulars/h/h
yzaar/hyzaar_pi.pdf

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684062.html

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=17bb21ce-9bb1-4603-b168-abea7fc85d17

https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682608.html

difficulty breathing, dizziness,
fainting

Propranolol
Hydrochloride

Quinapril
Hydrochloride

Sotalol
Hydrochloride

Verapamil
Hydrochloride

HTN

accupril,
accuprin,
acequin,
korec

HTN

HTN

HTN

synthetic betaadrenergic receptor
blocker
salt form of
quinapril, a prodrug
and non-sulfhydryl
angiotensin
converting enzyme
(ACE) inhibitor
with
antihypertensive
activity-leads to
vasodilation
antiarrhythmic drug
with betaadrenoceptor
blocker and cardiac
action potential
duration
prolongation
properties
calcium ion influx
inhibitor (slow
channel blocker)
modulates the influx
of ionic calcium
across the cell
membrane of

nausea, vomiting, epigastric
distress, abdominal cramping,
diarrhea, constipation, mesenteric
arterial thrombosis, ischemic
colitis, bronchospasm, Systemic
lupus erythematosus, dry eyes,
toxic epidermal necrolysis,
urticaria, skin issues

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=46942e6e-73bb-4687-853a-e3ec2734cc70

dizziness, lightheadedness,
tiredness, cough, nausea,
vomiting, fainting, muscle
weakness, slow/irregular HR,
change in amount of urine
(http://www.webmd.com/drugs/2/
drug-6254/quinapril-oral/details#)

http://pubchem.ncbi.nlm.nih.gov/compound/Accupri
l#section=Top

infection, fever, localized pain,
cardiovascular symptoms,
nervous system symptoms,
digestive, respiratory, urogenital,
metabolic, musculoskeletal, skin
rash, bleeding, visual problems

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=576905b7-6e6d-4aa0-b690-24be26e70cd2

constipation, headache, dizziness,
lethargy, dyspepsia, rash, ankle
edema, sleep disturbance, myalgia

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=3bee2d26-138c-4641-a217-a38d3d657461
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arterial smooth
muscle and
conductile and
contractile
myocardial cells
Verapamil
Hydrochloride
SR

see above

Tamsulosin
Hydrochloride

Flomax

Flomax
Norvasc
Lotrel
Tiazac

tamsulosin
hydrochlorid
e
see above
see above
diltiazem

Diltzac
Losartan
Potassium

HTN

not for use
in HTN
Not
indicated
for HTN

alpha 1
adrenoceptor
blocking agentselective for
prostrate

headache, infection, asthenia,
back pain, chest pain, nervous
system symptoms, respiratory,
digestive, urogenital symptoms,
blurred vision

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=d302b0fb-4f03-4106-b484-1e811f62c356

alpha adrenoceptor
antagonist

fainting, dizziness,
lightheadedness, rash, itching,
hives, runny nose, decreased
semen

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=c00d5f7b-dad7-4479-aae2-fea7c0db40ed

see above

diltiazem
hydrochlorid
e
see above
Each of these contains 100 units
of insulin as part per mL: 10 mL
vials, 3 mL Pen Fill cartridges,
3mL NovoLog FlexPen, 3 mL
NovoLog FlexTouch

Propranolol
Hydrochloride
LA

see above

long acting
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